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EXPLOITING CHEMOGENETIC AND GENETIC INTERACTIONS IN HUMAN CELLS
AS AN AVENUE FOR NEW THERAPEUTIC OPPORTUNITIES

Medina Colic, B.S.
Advisory Professor: Traver Hart, Ph.D.

The advent of CRISPR technology and its adaptation to the mammalian genome
made whole-genome knockout screens possible directly in human cells. Gene knockout
answers how essential that gene is for cell fitness and proliferation. Genes showing
moderate to severe fitness defects are called essential genes and provide insights into
disease-specific candidate therapeutic targets. Additionally, CRISPR offers other
applications for genome editing. Two applications this dissertation is based on are 1)
combination of gene knockout and drug treatment, which enables the identification of
chemogenetic interactions, or gene mutations that enhance or suppress the activity of a
drug, and 2) combinatorial editing, which facilitates the examination of possible genetic
interaction between the two perturbed genes. Both chemogenetic and genetic
interactions have the potential to decode the mechanisms of cancer diseases and
provide an avenue for new therapeutic strategies.
CRISPR-mediated chemogenetic screens have primarily been used in positive
selections screens. Therefore, allowing only the identification of genetic modifications
involved in resistance mechanisms. In the first part of this dissertation, I describe drugZ,
an algorithm that addressed the need for identifying both, genetic modifications involved
in synthetic lethality as well as in resistance mechanisms. In addition to identifying known
and novel chemogenetic interactions, I show that drugZ also provides insights into the
experimental design of pooled CRISPR screens. The second part of this dissertation is
focused on predicting the synthetic lethal interactions, which are the most frequently
viii

investigated genetic interactions. Very few of these interactions have been reproduced
across multiple studies and many appear highly context-specific. Thus, the major
drawback is the lack of gold standards synthetic lethal interactions and a baseline
probability of being synthetic lethal for any given gene pair, independent of the molecular
background. I address this drawback by predicting the context-independent synthetic
lethal probability with Bayes’ theorem, through the integration of existing CRISPR-based
genetic interaction screens and other functional genomics data types.
Collectively, this work provides analytical methods that advance the field of
functional genomics, a significant understanding of chemogenetic and genetic
interactions in human cancer cells, insights about optimized, less time and effortconsuming experimental design, and an avenue for generating new therapeutic
opportunities.
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Chapter 1: Introduction
1.1 Permission to use previously published works
Some introduction content is based upon the review articles 1) Chemogenetic
Interactions in Human Cancer Cells by Medina Colic and Traver Hart in the
Computational and Structural Biotechnology Journal Science Direct on November 7,
2019 (https://doi.org/10.1016/j.csbj.2019.09.006)(Colic & Hart, 2019). The following
is from the publisher: “This is an open access article distributed under the terms of
the Creative Commons CC-BY license, which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited. Please
note that, as one of the Authors of this article, you retain the right to reuse it in your
thesis/dissertation. You do not require formal permission to do so. You are permitted
to post this Elsevier article online if it is embedded within your thesis. Suitable
acknowledgement to the source must be made, either as a footnote or in a reference
list at the end of your publication. You are also permitted to post your Author Accepted
Manuscript online.” and 2) Common Computational Tools for Analyzing CRISPR
Screens by Medina Colic and Traver Hart in the Emerging Topics in Life Sciences,
Portland

Press,

on

December

9,

2021,

under

CC

BY

license

(https://doi.org/10.1042/ETLS20210222)(Colic & Hart, 2021). The following is from
the publisher: “Permission to reuse content from an article published by Portland
Press:
•

If the content that you are seeking to re-use is in a Portland Press article that is
published open access under a CC BY licence NO permissions are required,
although you must cite the published article and credit the authors when you reuse it (or part of it).
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•

If the article you are seeking to re-use is published open access under any other
type of licence (e.g. CC BY NC-ND) or a Portland Press license to publish then
please complete a re-use permission-request form via copyright.com.

•

To find out what licence the article is published under look for the copyright line
on the published article, which can be found underneath the abstract or full text,
depending on what view you are seeing for the article.

•

FOR AUTHORS: if you are a named author on the article you wish to re-use then
you will not need to seek any permissions except for re-use of non-open access
papers that involves commercial re-selling or bulk distribution. For the latter,
please visit copyright.com.”

“Every object that biology studies is a system of systems.” (Jacob, 1977).

1.2 The emergence of functional genomics and systems biology
Functional genomics is a field aiming to characterize gene (and protein) functions
and interactions, and how they contribute to different biological processes. The key
property of functional genomics is addressing and modeling genetic questions and
concepts on a modular basis, i.e., groups of genes, protein complexes, or pathways,
rather than a traditional single-gene approach. Therefore, the goal of functional
genomics is to learn how the individual components of a biological system work
together to produce a certain phenotype. Alongside functional genomics, systems
biology is another field that studies complex interactions genome-wide or systemwide. Systems biology uses quantitative analysis and computational modeling of
molecular components on different levels of single and multiple biological units (e.g.,
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pathways, cell, tissue, and organ systems) to capture and explain the biological
system as a whole.
The availability of a complete genome sequence for an organism leads to
improved annotations of genes and proteins, therefore facilitating the understanding
of interactions and molecular processes in the cell through genome-wide studies.
Saccharomyces cerevisiae or budding yeast is the first eukaryotic organism to have
its complete genome sequenced in 1996 (Goffeau et al., 1996). A myriad of studies
using yeast as a model system has established that disrupting a gene is a
fundamental approach for determining the consequences of loss of gene function and
is used to exploit the functional role of a gene (Botstein et al., 1997; Botstein & Fink,
1988; Esser et al., 1999; Giaever et al., 2002a; Giaever & Nislow, 2014; Vandenbol
& Fairhead, 2000; Winzeler et al., 1999). Yeast was and is a model of choice in many
genetic investigations because it is one of the simplest eukaryotic organisms which
shares many essential cellular processes with human cells. The human genome was
completely sequenced in 2001 (Lander et al., 2001), not too long after the
completeness of yeast genome sequencing, hence initiating the avalanche of
functional genomics and systems biology studies using the human cell as a model
organism.

1.3 Functional profiling in yeast

The main contribution yeast studies provided to the scientific community is the
connections identified between genes and proteins with corresponding functions they
perform within a cell. Two decades ago, Giaever et al. generated an almost complete
(96% of annotated open reading frame, ORFS) collection of gene-deletion mutants
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of the Saccharomyces cerevisiae yeast (Giaever et al., 2002a) and found that most
yeast genes (~80%) have no obvious phenotypic effect in rich medium. To uncover
phenotypes for these 80% genes, Hillenmeyer et al. performed 1144 chemical
genomic assays on the yeast whole-genome heterozygous and homozygous deletion
collections and quantified the growth fitness of each deletion strain in the presence
of chemical or environmental stress conditions (Hillenmeyer et al., 2008). They found
that 97% of gene deletions exhibited a measurable growth phenotype, suggesting
that nearly all genes are essential for optimal growth in at least one condition. These
and similar large-scale functional profiling studies (Baudin et al., 1993; Burns et al.,
1994; Hillenmeyer et al., 2010; Ooi et al., 2006; Pan et al., 2004; Ross-Macdonald et
al., 1999, p.; Shoemaker et al., 1996) led to the systematic mapping of genetic
interactions in yeast, resulting in an assembly of a hierarchical model of cell function.
The systematic mapping of genetic interactions, described in great detail by Dixon et
al. (Dixon et al., 2009), is done through several steps:
-

Generate double mutants, which in yeast are created by mating the query and
deletion strains.

-

Score the double mutant phenotype, with respect to the corresponding single
mutant phenotypes.

-

Construct and interpret the resulting genetic interaction matrix.

The most widely studied and characterized types of genetic interactions are negative
(synthetic sickness or lethality, SL) and positive (buffering or suppression) genetic
interactions. The comparisons and measurements within each type are based on the
wild-type strain fitness. In negative genetic interactions, the observed double mutant
fitness (DMF) is less than the expected DMF which is calculated as a product of two
single mutant fitnesses (SMF). Whereas in positive interactions, the observed DMF
4

is greater than or has a positive deviation from the expected DMF, again calculated
as a product of SMFs. The global network of genetic interactions in yeast has been
constructed by Costanzo et al. using the functional data, which revealed that genes
from a similar biological process cluster together in coherent modules, and correlated
profiles outline specific pathways to elucidate gene function (Costanzo et al., 2010a,
2016, 2019). Until recently, these large-scale functional studies were performed out
only in simple model organisms, because there was no proper technology to facilitate
similar studies directly in human cells.

1.4 Functional profiling in human cells
The three requirements for successful genome editing are:
•

Recognize a specific, RNA sequence of interest

•

Be able to cut that DNA sequence

•

Be easily reprogrammable to target and cut different DNA sequences
A crack in creation, Jennifer A. Doudna

The first two requirements are necessary for generating a double-strand break
(DSB) which would induce the changes in gene products, and the last one is essential
for the tool to be broadly used and applicable. Previously proposed gene-editing
techniques such as I-SceI, rare cutting endonuclease, Zinc finger nucleases (ZNF),
and Transcription activator-like effector nucleases (TALENs) were successful at
partially satisfying the first two criteria but failed greatly at the last requirement.
Therefore, being bypassed by more precise, robust, and scalable technologies such
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as RNA interference and possibly ultimate gene editing technology Clustered
regularly interspaced short palindromic repeats (CRISPR).

1.4.1 RNA interference (RNAi)
Post-transcription gene silencing (PTGS), RNA silencing, or RNAi is a process
with an essential role in immunity, the regulation of protein synthesis, and a genetic
tool for manipulating gene expression. RNAi regulates gene expression through
double-stranded RNAs (dsRNAs), introduced into a cell by a virus or are already
produced in the cell, which give rise to small interfering RNAs (siRNAs) that guide
mRNA degradation (Meister & Tuschl, 2004; Montgomery, 2004). The RNAi-like
process was first reported in plants as a cosuppressing phenomenon (Napoli et al.,
1990) and as a preventative mechanism for transposable elements integration and
RNA viruses (Waterhouse et al., 2001). After plants, similar events of unanticipated
gene silencing have been observed in other organisms as well, quelling in fungi, and
RNA silencing in animals, first in Caenorhabditis elegans nematodes (Fire et al.,
1998), and later in Drosophila melanogaster flies (Kennerdell & Carthew, 1998).
Briefly, after the sequencing of the complete human genome, RNAi technology
using siRNA and short hairpin RNA (shRNA) libraries has been widely utilized for
both, small-scale gene characterization studies and large-scale genomic screening
in human cells (Echeverri & Perrimon, 2006; Paddison & Hannon, 2002; J. Silva et
al., 2004). shRNAs are vector-based and synthesized in the nucleus of a cell,
opposite to siRNAs which restrict the RNAi in human cells to the cytoplasm (Rao et
al., 2009). These efforts have led to the identification of new components of the p53
pathway (Berns et al., 2004), genetic suppressor of RAS activity and tumorigenicity
(Kolfschoten et al., 2005), candidate tumor suppressors (Westbrook et al., 2005), SL
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relationships (Rottmann et al., 2005), the function of human kinases in endocytosis
(Pelkmans et al., 2005), essential genes for mitotic progression and proliferation
(Moffat et al., 2006), cell division (Kittler et al., 2004), and other core biological
processes (Luo et al., 2008; Schlabach et al., 2008; J. M. Silva et al., 2008). These
findings were a precursor for the identification of the initial set of core essential genes
which are expected to be essential across all contexts (Hart et al., 2014), and contextspecific essential genes or cancer-specific genetic vulnerabilities (Cheung et al.,
2011; Cowley et al., 2014; Marcotte et al., 2012; McDonald et al., 2017; Tsherniak et
al., 2017). Despite the promising results, RNAi technology has a few shortcomings:
incomplete silencing or knockdown (Boettcher & McManus, 2015; Sigoillot & King,
2011; Taxman et al., 2010), off-target effects (Birmingham et al., 2006; Horn et al.,
2010; Jackson et al., 2003; Qiu, 2005), signal noise and high false-negative rate (Hart
et al., 2014; Hong et al., 2014; Hu, 2004), stimulated immune response (Kanasty et
al., 2012; Meng & Lu, 2017), and laborious analysis and validation. These
confounding effects limited the use of this technology and prompted caution when
interpreting and relying on RNAi-produced results.

1.4.2 CRISPR technology

The advent of CRISPR technology and its adaptation to mammalian cells enabled
whole-genome genetic perturbations directly in human cells. CRISPR-associated
(Cas) protein or a nuclease and a single guide RNA (sgRNA), which is designed to find
and bind to a target of interest DNA sequence, are two main components of the
CRISPR editing system. In CRISPR screening, cells of interest are treated with
CRISPR libraries which are collections of lentiviral vectors that encode sgRNA and Cas
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protein. The CRISPR–Cas system utilizes the Cas nuclease, which is guided to the
target sequence by a gRNA, where it introduces a double-strand break at the desired
locus (Figure 1.A). Activation of error-prone repair by nonhomologous end-joining
pathways (NHEJ) results in a frameshift mutation creating a gene knockout (KO). When
DNA damage is too great a burden on the model systems, alternative, engineered Cas
approaches are available. Nuclease-inactivated ‘dead' Cas9 (dCas9) can be fused with
transcriptional activation or repression domains and targeted to gene promoters to
activate (CRISPRa) or repress/inhibit (CRISPRi) gene transcription (Figure 1.B,C).
dCas9 systems have been reviewed in greater detail by Kazi and Biswas (Kazi &
Biswas, 2021).
Gene KO is the most widely used tool in the CRISPR toolkit. CRISPR KO screens
answer how essential, or how necessary a gene is for a cellular fitness, with genes
showing moderate to severe fitness defects often called ‘fitness genes' or ‘essential
genes'. Exceptional examples of genome-wide CRISPR KO screens are two large pancancer CRISPR–Cas9 studies performed by the Broad Institute and the Wellcome
Sanger Institutes (Behan et al., 2019; Meyers et al., 2017), in which over a thousand
cancer cell lines were screened with genome-scale KO screens. In addition to
individual efforts, these two institutes work collaboratively (Boehm et al., 2021;
Dempster et al., 2019; Pacini et al., 2021) with an aim of creating a comprehensive
map of all the intracellular genetic dependencies and vulnerabilities of cancer, known
as the Cancer Dependency Map (DepMap) project (Broad Institute, 2019; Sanger
Institute, 2019). Such efforts hold a premise of providing a comprehensive
representation of cancer heterogeneity and an avenue for developing new therapies.
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The emergence of CRISPR-mediated genetic screens and continued improvement
in CRISPR reagent design (Doench et al., 2016; Gonçalves et al., 2021; Hart et al.,
2017) has enable investigation of genome-wide and custom libraries gene-drug
interaction in human cells (Deans et al., 2016; Estoppey, Hewett, et al., 2017;
Estoppey, Lee, et al., 2017; Hustedt et al., n.d.; MacLeod et al., 2019; Noordermeer et
al., 2018; Olivieri et al., 2020; Shalem et al., 2014; Su et al., 2020; C. Wang et al., 2018;
T. Wang et al., 2014; Yoshimoto et al., 2012; Zimmermann et al., 2018). These studies
illustrated the power of chemogenetic screens (CRISPR + drug perturbation) (Figure
1.D) in identifying new genetic vulnerabilities to PARP, ATR, BRAF, NAMPT inhibitors,
and temozolomide, and shed a light on using such experimental set-ups for a discovery
of novel therapeutic targets. I provide a comprehensive overview of chemogenetic
screens in human cancer cell lines in our review (Colic & Hart, 2019) of this topic and
later in this chapter.

In comparison with cell culture, in vivo systems are preferred for translational
cancer research (e.g., evaluating tumor progression and therapeutic response), as they
provide a more clinically relevant environment for tumor modeling. CRISPR editing in
in vivo model in conducted by creating the mutant cell population of interest in a dish
and then implanting those into a mouse, often subcutaneously or intravenously (Figure
1.D). In the last few years, CRISPR technology has been used in living model
organisms for studying various cancers and cancer specific processes (Bajaj et al.,
2020; Dai et al., 2021; Dong et al., 2019; Gautron et al., 2021; Griffin et al., 2021;
Manguso et al., 2017; van der Weyden et al., 2021), though the complexity of the
approach limits these screens to targeted gene panels.
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CRISPR screens are being used in immune-oncology studies as well, with the most
common approach being to proliferate CRISPR-mutagenized cells in the presence or
absence of T cells (or other immune system components) (Figure 1D). In the recent
years, pooled CRISPR screens in tumor/immune co-culture systems have provided
insights into tumor mechanisms that cause resistance to immunotherapies (Hou et al.,
2021; Lawson et al., 2020), genes involved in the immune synergistic interactions
(Lawson et al., 2020), and identification of novel targets for immune-oncology (Mair,
Aldridge, et al., 2019). The studies described in the review focusing on interrogating
immune cells and cancer with CRISPR–Cas9 (Buquicchio & Satpathy, 2021) are the
proof that the CRISPR screens are a powerful tool for investigating tumor–immune coculture systems.

Though these approaches offer an enormous advantage over the prior state-of-theart, widespread genetic buffering imposes clear constraints on the ability of monogenic
KO systems to provide saturating screens. These constraints have driven the
development of multiplex targeting platforms via the delivery of multiple sgRNAs per
cell. This can be facilitated by using two Cas9 nucleases derived from different bacterial
species, e.g., S. pyogenes and S. aureus, with species-specific gRNA expressed from
different promoters (e.g., hU6 and mU6) (Figure 1.E). Other systems use a single
SpCas9 with two gRNA expressed from different promoters (Figure 1.E). Lastly,
enhanced Cas12a (enCas12a) multiplex platform (Figure 1.F), is the current state of
the art combinatorial editing system. The enCas12a nuclease can process multiple
gRNA from a single polycistronic transcript and offers an attractive alternative to Cas9
for multiplex screening, which facilitates the large-scale investigation of genetic
interactions in mammalian cells. In the DeWeirdt et al. study, which optimized libraries
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for the engineered enCas12a variant, the group also screened for synthetic lethality
(SL) in two cancer cell lines (OVCAR8 and A375) and discovered previously
unreported interaction between MARCH5 and WSB2 (DeWeirdt et al., 2021). Dede et
al. has utilized the enCas12a platform to investigate the functional buffering among
∼400 candidate paralog pairs in three cell lines (Dede et al., 2020). The authors
observed 24 SL paralog pairs that were previously undetected by monogenic KO
screens. The Moffat group took advantage of the Cas12a system in a different fashion
— combing Cas9 and Cas12a to create a hybrid Cas platform, CHyMErA, to evaluate
a set of 672 human paralog pairs, and explore chemogenetic interactions in the mTOR
pathway (Gonatopoulos-Pournatzis et al., 2020). The research produced by combined
multiplex targeting systems has shown the potential to identify context-specific genetic
interactions, candidate combinatorial drug treatments, and potential drug targets
(Boettcher et al., 2018; DeWeirdt et al., 2020; Diehl et al., 2021; Ito et al., 2021, p. 4;
Najm et al., 2018; Parrish et al., 2021; Shen et al., 2017; Thompson et al., 2021; Wong
et al., 2016), but experimental design and analysis of these screens are highly complex.
The rest of this chapter will focus on two of these applications, chemogenetic
screens and combinatorial editing. The quantitative approaches for addressing the
gaps in chemogenetic and genetic interactions in human cells are the central topic of
this dissertation.
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Figure 1. CRISPR Toolbox.
interference.
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CRISPR.

B)

CRISPR activation.

C)

CRISPR

Pooled screens: 1. In vivo, 2. Chemogenetic, 3. Immuno-oncology,

and 4) Isogenic screens.

E)

Cas9 multiplex platforms: 1. Single Cas9 (e.g., S.

pyogenes) system using two copies of the U6 promoter. 2. Single Cas9 system uses
two different promoters. 3. A two Cas9, two different promoters’ system. F) EnCas12a
multiplex platform.
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1.5 Genetic interactions and their relevance in cancer

To quantify genetic interaction between two genes, a simultaneous digenic
perturbation would have to be performed. However, despite the great use of CRISPR
technology, genome-wide digenic perturbations are still not feasible in human cells,
because scalability is an issue. The human genome encompasses ~20,000 proteincoding genes, and it would take ~400 million perturbations to screen all combinations
of these protein-coding genes. Therefore, few groups including us in Hart lab have
used indirect methods (Boyle et al., 2018; E. Kim et al., 2019a; T. Wang et al., 2017a)
to derive functional interactions from DepMap CRISPR KO screens performed in
~1000 cancer cell lines. These indirect methods of deriving functional interactions are
based on the observation that genes with correlated essentiality profiles in human cell
lines are analogous to genes having correlated genetic interaction profiles in yeast cells,
implying co-functionality and shared biological function. Genetic interactions are
relevant in cancer because most biological and disease-related phenotypes are
controlled by more than one gene. Cancer cells arose due to genetic changes, which
can be the gain of function or loss of function events. Targeting cancers driven by the
gain of function events is a strategy relying on pharmacological targeting of the
oncogene. Inhibiting BCR-ABL fusion oncogene in Chronic Myelogenous Leukemia
(CML) is one of the early examples of an oncogene-targeted therapy (Savage &
Antman, 2002). Whilst targeting cancers driven by the loss of function events, such
as the loss or mutation of a tumor suppressor gene (TSG), is much more challenging.
This challenge is due to the loss of a relevant gene from tumor cells, making it
impossible for a relevant gene to be a direct pharmacological target. In those cases,
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SL interactions can be used to tailor a therapeutic strategy. For example,
BRCA1/BRCA2

(breast

cancer-associated

proteins)-deficient

cells

are

hypersensitive to the inhibition of poly adenosine-diphosphate ribose polymerase
(PARP), suggesting SL between TSGs BRCA1/BRCA2 and PARP (Ashworth,
2008a). These findings led to successful use of PARP inhibitors in several BRCAdeficient cancer types, establishing a promise for using SL towards strategizing
cancer treatments. As such, SL interactions are the most frequently studies and
widely characterized genetic interaction. However, through my analysis of existing
CRISPR-mediated genetic interactions studies in human cells, we observed that very
few of these SLIs are reproduced as significant across multiple studies, and many of
them are context-specific. Therefore, indicating the need for some baseline
probability of being a SL for any given gene pair.

1.6 Chemogenetic interactions in human cancer cells

In addition to its use for functional genomics, the rapid development of genome
wide CRISPR KO screens in mammalian cells has also led to the emergence of
chemogenetic screening in human cells. Genome-wide CRISPR KO screens can be
divided into two types: positive screens and negative screens. CRISPR-mediated
chemogenetic screens have been mainly used in positive selection screens, which
provide insights into genetic mechanisms of drug resistance. The signal for positive
selection screens is generally strong, as only mutant cells with resistance genes
survive. Such approach has been successfully used to identify genes driving
resistance to target therapies, including BRAF and MEK inhibitors, and other drugs
(Krall et al., 2017; Shalem et al., 2014; T. Wang et al., 2014). Contrarily,
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chemogenetic screening in negative selection screens is more complex. Negative
selection screens are often used to identify genes whose KO leads to moderate
fitness defects. The studies in yeast genetics indicate that genes with moderate
fitness defects have more synergistic genetic interactions than those genes without
any fitness defect (Costanzo et al., 2010a). In CRISPR screens in mammalian cells,
moderate fitness defects are reflected in lower gRNA read counts at later time points
in an experiment. Therefore, adding the drug treatment, can decrease even further
the experimental readout (i.e., gRNA read counts) which makes the identification of
genes with moderate fitness defects under that treatment even more analytically
challenging.

1.7 Dissertation overview
The efforts to decode complex diseases such as cancer and devise treatment
strategies accordingly have gone long way. The advent of CRISPR technology has
revolutionized cancer biology through the discovery of essential genes for drug
targets, identification of metastatic regulators, drug resistance mechanisms,
immunotherapy targets, and SL, all of which are fundamental for cancer treatment
opportunities.

The overall objective of this dissertation is to exploit and characterize
chemogenetic and genetic interactions in human cells to advance our understanding
of genetic modifiers of drug activity and provide a strategy for identifying candidate
tumor-specific therapeutic targets. Chapter 2 describes the chemogenetic screens
and features the implementation of the drugZ algorithm for identifying both synergistic
and suppressor chemogenetic interactions from CRISPR screens. Additionally, in this
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chapter, I provide recommendations for parameter choice and experimental design
based on drugZ analyses, and I show that drugZ robustly identifies known and novel
chemogenetic interactions. Lastly, this chapter highlights our observation that a small
set of tumor suppressor genes are frequent drug suppressor hits across several
screens using different drugs or small molecule perturbagens with distinct
mechanisms of action, suggesting that these hits are drug-agnostic proliferation
suppressor hits in chemogenetic screens. Chapter 3 focuses on the challenge of
predicting the context-independent SL and the approach I am proposing to address
it. This 10-step approach predicts the probability of being a SL for any given gene
pair and is based on integrating data from existing CRISPR-mediated genetic
interaction screens and 30 features derived from essentiality, expression,
protein/genomic neighborhood, and sequence-based data. Finally, this chapter
demonstrates the number of features set | model performance comparisons aiming
to identify the optimal set of features and evaluate the best model. Chapter 4 outlines
several collaborative studies based on utilizing CRISPR technology towards
identifying disease-specific candidate therapeutic targets, featuring my contributive
work. At last, chapter 5 outlines the conclusions from previous chapters and final
remarks and provides insights into a few directions I foresee this study evolving.
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Chapter 2: Identifying chemogenetic interactions from CRISPR screens with
drugZ

This chapter is based on a published article: Identifying Chemogenetic
Interactions from CRISPR Screens Using DrugZ published by Medina Colic, Gang
Wang, Michal Zimmermann, Keith Mascall, Megan McLaughlin, Lori Bertolet, W.
Frank Lenoir, Jason Moffat, Stephane Angers, Daniel Durocher and Traver Hart in
the BCM Genome Medicine on August 22, 2019 (https://doi.org/10.1186/s13073-0190665-3) (Colic et al., 2019). The following is from the publisher: “This article is
distributed under the terms of the Creative Commons Attribution 4.0 International
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided you give appropriate
credit to the original author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated.”

2.1 Abstract

Background
Chemogenetic profiling enables the identification of gene mutations that
enhance or suppress the activity of chemical compounds. This knowledge provides
insights into drug mechanism of action, genetic vulnerabilities, and resistance
mechanisms, all of which may help stratify patient populations and improve drug
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efficacy. CRISPR-based screening enables sensitive detection of drug-gene
interactions directly in human cells, but until recently has primarily been used to
screen only for resistance mechanisms.

Results
We present drugZ, an algorithm for identifying both synergistic and suppressor
chemogenetic interactions from CRISPR screens. DrugZ identifies SL interactions
between PARP inhibitors and both known and novel members of the DNA damage
repair pathway, confirms KEAP1 loss as a resistance factor for ERK inhibitors in
oncogenic KRAS backgrounds, and defines the genetic context for temozolomide
activity.

Conclusions
DrugZ is an open-source Python software for the analysis of genome-scale
drug modifier screens. The software accurately identifies genetic perturbations that
enhance or suppress drug activity. Interestingly, analysis of new and previously
published data reveals tumor suppressor genes are drug-agnostic resistance genes
in drug modifier screens. The software is available at github.com/hart-lab/drugz.

2.2 Background
The ability to systematically interrogate multiple genetic backgrounds with
chemical perturbagens is known as chemogenetic profiling. While this approach has
many applications in chemical biology, it is particularly relevant to cancer therapy,
where clinical compounds or chemical probes are profiled to identify mutations that
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inform on genetic vulnerabilities, resistance mechanisms, or targets (Hartwell, 1997).
Systematic surveys of the fitness effects of environmental perturbagens across the
yeast deletion collection (Giaever et al., 2002b) offered insight into gene function at
a large scale, while profiling of drug sensitivity in heterozygous deletion strains
identified genetic backgrounds that give rise to increased drug sensitivity (Giaever et
al., 1999). Now, with the advent of CRISPR technology and its adaptation to pooled
library screens in mammalian cells, high-resolution chemogenetic screens can be
carried out directly in human cells (Doench et al., 2016; Jinek et al., 2012; Shalem et
al., 2014; T. Wang et al., 2014). Major advantages to this approach include the ability
to probe all human genes, not just orthologs of model organisms; the analysis of how
drug-gene interactions vary across different tissue types, genetic backgrounds, and
epigenetic states; and the identification of suppressor as well as synergistic
interactions, that may preemptively indicate mechanisms of acquired resistance or
pre-existing sources of resistant cells in heterogeneous tumor populations.

Design and analysis of CRISPR-mediated chemogenetic interaction screens
in human cells can be problematic. Positive selection screens identifying genes
conferring resistance to cellular perturbations typically have a high signal-to-noise
ratio, as only mutants in resistance genes survive. This approach has been used to
identify genes conferring resistance to targeted therapeutics, including BRAF and
MEK inhibitors, as well as other drugs (Shalem et al., 2014)(Blondel et al., 2016;
Doench et al., 2016; Konermann et al., 2015; Krall et al., 2017; le Sage et al., 2017;
Liao et al., 2017; T. Wang et al., 2014; Zhang et al., 2016). Conversely, negative
selection CRISPR screens require growing perturbed cells over 10 or more doublings
to allow sensitive detection of genes whose KO leads to moderate fitness defects.
19

Adding the detection of drug interactions to these experiments necessitates dosing
at sub-lethal levels to balance between maintaining cell viability over a long time
course and inducing drug-gene interactions beyond native drug effects (Estoppey,
Hewett, et al., 2017; Estoppey, Lee, et al., 2017; C. Wang et al., 2018; Zimmermann
et al., 2018).

In this study, we describe drugZ, an algorithm for the analysis of CRISPRmediated chemogenetic interaction screens. We apply the algorithm to identify genes
that drive normal cellular resistance to the PARP inhibitor olaparib in three cell lines.
We demonstrate the greatly enhanced sensitivity of drugZ over contemporary
algorithms (Doench et al., 2016) (W. Li et al., 2014; Luo et al., 2008; Robinson et al.,
2010) by showing how it identifies more hits with higher enrichment for the expected
DNA damage response pathway, and further how it identifies both synergistic and
suppressor interactions. We further demonstrate the discovery of both synergistic and
suppressor interactions in a single experiment with KRAS-mutant pancreatic cancer
cell lines treated with an ERK inhibitor, and through reanalysis of published data.
Interestingly, we observe a trend across several datasets where tumor suppressor
genes score as drug suppressors, indicating a possible systematic source of false
positives. We provide all software and data (Colic & Hart, Traver, n.d.) necessary to
replicate the analyses presented here; see “Availability of data and materials” below
for links.
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2.3 Implementation
2.3.1 DrugZ algorithm
We calculate the log2 fold change of each gRNA in the pool by normalizing the
total read count of each sample (to n = 10 million reads) at the same time point and
taking the log ratio, for each replicate, of treated to control reads.
𝑓𝑐𝑟 = log 2 [

𝑛𝑜𝑟𝑚(𝑇𝑡,𝑟 ) + 𝑝𝑠𝑒𝑢𝑑𝑜𝑐𝑜𝑢𝑛𝑡
𝑛𝑜𝑟𝑚(𝐶𝑡,𝑟 ) + 𝑝𝑠𝑒𝑢𝑑𝑜𝑐𝑜𝑢𝑛𝑡

]

where:

•

fc = fold change

•

r = replicate indication

•

T = treated sample

•

C = control sample

•

t = time point

•

pseudocount = default value is 5

We estimate the variance of each fold change by calculating the standard deviation
of fold changes with similar abundance in the control sample:

sort(fc𝑟) according 𝐶𝑟 (descending=True)
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𝑁

𝑒𝑏_𝑠𝑡𝑑𝑓𝑐𝑟

1
= √ ∑(𝑓𝑐𝑟,𝑖 − 𝜇)2
𝑁
𝑖

where:

•

eb_stdfc𝑟 = estimated variance

•

N = number of fold changes with similar abundance (default = 1000)

•

i = guide

•

fcr, i = fold change for each guide in a replicate

•

μ=0

and then calculate a Z-score for each fold change using this estimate:

𝑧𝑓𝑐𝑟,𝑖 =

𝑓𝑐𝑟,𝑖
𝑒𝑏_𝑠𝑡𝑑𝑓𝑐𝑟,𝑖

The guide Z-score of all gRNA across all replicates is summed to get a gene-level
sumZ score, which is then normalized (by dividing by the square root of the number
of summed terms) to the final normZ (Figure 2.B):

𝑛𝑜𝑟𝑚𝑍𝑔𝑒𝑛𝑒𝐴 =

∑ 𝑍𝑓𝑐𝑟,𝑖

𝑔𝑒𝑛𝑒𝐴

√𝑛
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Figure 2. Workflow. A) Experimental design. In a drug-gene interaction screen, cells
are transduced with a pooled CRISPR library. Cells are split into drug-treated and
untreated control samples, grown for several doublings; genomic DNA is collected;
and the relative abundance of CRISPR gRNA sequences in the treated and control
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population is compared. B) DrugZ processing steps include normalizing read counts,
calculating fold change, estimating the standard deviation for each fold change, Zscore transformation, and combining guide scores into a gene score. C-E) Comparing
existing methods vs. drugZ for SUM149PT olaparib screen. DrugZ hits show
strongest enrichments for DDR genes across a range of FDR thresholds. C) Number
of raw hits. D) Number of annotated DNA damage response (DDR) genes in hits. E)
−log P values for DDR gene enrichment by hypergeometric test.

A P-value is calculated from the normZ, and corrected for multiple hypothesis testing
using the method of Benjamini and Hochberg (Benjamini & Hochberg, 1995). The
open-source Python software can be downloaded from github.com/hart-lab/drugz.

2.3.2 DrugGS algorithm
After empirical Bayes variance estimation approach is applied on normalized
log-fold changes to calculate a Z-score for each guide, we applied Gibbs sampling to
generate posterior distribution of fold changes for each gene.
𝑃𝑜𝑠𝑡𝑒𝑟𝑖𝑜𝑟 ~ 𝐿𝑖𝑘𝑒𝑙𝑖ℎ𝑜𝑜𝑑 ∗ 𝑃𝑟𝑖𝑜𝑟
𝑃(𝜇, 𝜏| 𝑑𝑎𝑡𝑎) =
𝑃(𝑑𝑎𝑡𝑎|𝜇, 𝜏)
𝑃(𝜇, 𝜏)

𝑃(𝑑𝑎𝑡𝑎|𝜇, 𝜏) ∗ 𝑃(𝜇, 𝜏)
𝑃(𝑑𝑎𝑡𝑎)

𝑝𝑜𝑠𝑡𝑒𝑟𝑖𝑜𝑟
𝑙𝑖𝑘𝑒𝑙𝑖ℎ𝑜𝑜𝑑
𝑝𝑟𝑖𝑜𝑟

Each gene has a distribution composed of Z-scores for guides targeting that specific
gene across replicates. Distribution is characterized as ℕ(𝜇, 𝜏), 𝑤ℎ𝑒𝑟𝑒 𝜏 𝑖𝑠

1
𝜎2

.

24

Both 𝜇 and 𝜏 have hyperparameters (𝜇: 𝜇, 𝜎 2 , 𝜏: 𝑎, 𝑏) that we initialize at the very start
of sampling.
𝑃(𝜏|𝑑𝑎𝑡𝑎)~ Γ(a, b) = 𝐺𝑎𝑚𝑚𝑎 𝑝𝑟𝑖𝑜𝑟 𝑤𝑖𝑡ℎ 𝑎 (𝑠ℎ𝑎𝑝) 𝑎𝑛𝑑 𝑏 (𝑟𝑎𝑡𝑒) ℎ𝑦𝑝𝑒𝑟𝑝𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟𝑠.
𝑃(𝜇|𝜏, 𝑑𝑎𝑡𝑎)~ℕ(𝜇, 𝜎 2 )
= 𝑁𝑜𝑟𝑚𝑎𝑙 𝑝𝑟𝑖𝑜𝑟 𝑤𝑖𝑡ℎ 𝜇 (𝑚𝑒𝑎𝑛) 𝑎𝑛𝑑 𝜎 2 (𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒) ℎ𝑦𝑝𝑒𝑟𝑝𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟𝑠.
We then update 𝜇 and 𝜏 with respect to their priors in every 1000 samples that we
generate for each gene.
Equations to update 𝜇:
𝜇𝑢𝑝𝑑𝑎𝑡𝑒 =

(𝑛 ∗ 𝑦̅ ∗ 𝜏) + (𝜇𝑝𝑟𝑖𝑜𝑟 ∗ 𝜏𝑝𝑟𝑖𝑜𝑟 )
𝑛 ∗ 𝜏 + 𝜏𝑝𝑟𝑖𝑜𝑟

𝜎𝑢𝑝𝑑𝑎𝑡𝑒 =

1
√𝑛 ∗ 𝜏 + 𝜏𝑝𝑟𝑖𝑜𝑟

Equations to update 𝜏:
𝑎𝑢𝑝𝑑𝑎𝑡𝑒 = 𝑎𝑝𝑟𝑖𝑜𝑟 +

𝑛
2

𝑏𝑢𝑝𝑑𝑎𝑡𝑒 = 𝑏𝑝𝑟𝑖𝑜𝑟 + ∑(𝑍𝑓𝑐𝑟,𝑖 − 𝜇)2
where:
•

n = number of data points (guide Z-scores) for each gene

•

𝑦̅ = actual mean of data points

From those 1000 newly sampled 𝜇 and 𝜏, we then calculate the mean and standard
deviation. Each gene’s 𝜇 posterior distribution’s mean is what was converted into Zscore and used to compare with the drugZ normZ values.

𝑍𝑔𝑒𝑛𝑒𝐴

∑𝑆𝑘=1 𝜇𝑘
=
𝑆
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Where:
•

S = number of samples (in our case 1000)

•

k = sample

2.3.3 CRISPR screening
Drug-gene interaction screens
Olaparib

screens

were

described

in

(Zimmermann

et

al.,

2018).

Temozolomide screens were described in (MacLeod et al., 2019).

Cell culture
hTERT RPE-1 (CRL-4000) and 293T (CRL-3216) cells were purchased from
the ATCC and grown in Dulbecco’s High Glucose Modified Eagle Medium (DMEM;
HyClone) with 10% fetal bovine serum (FBS), 1 X GlutaMAX (Gibco), 100mM sodium
pyruvate (Gibco), 1 X non-essential amino acids (NEAA), 1X penicillin-streptomycin
(Pen/Strep), and 5ug ml-1 Plasmocure. Incubator conditions were kept at 37 oC with
5% CO2.

Lentivirus production
For production of the TKOV3 lentivirus, 9.0 X 106 293T cells were transfected
with psPAX2 (lentiviral packaging; Addgene #12260), pMD2.G (VSV-G envelope;
Addgene #12259), and TKOV3 (Toronto KnockOut CRISPR Library; Addgene
#90294) using X-tremeGENE 9 DNA transfection reagent (Sigma-Aldrich) in medium
with lowered antibiotic concentration (0.1X Pen/Strep). Medium was replaced with
viral harvest medium (DMEM + 1.1% BSA + 1X Pen/Strep) 18 hours posttransfection. Virus-containing supernatant was collected ~24-48 hours post26

transfection, and fresh viral harvest medium was added to transfected plates. Viruscontaining supernatant was collected again ~24 later. The virus-containing
supernatant was centrifuged to remove cell debris and stored at -80oC.

CRISPR screening
For transduction of the hTERT RPE-1 cells, the TKOv3 virus was added with
8ug/ml Polybrene. For selection of the transduced cells, puromycin was introduced
at a concentration of 20 ug/ml at 24 hours post-infection (the hTERT cassette used
to immortalize RPE1 cells contains a puromycin resistance marker, necessitating
extreme puromycin concentrations for selection). Puromycin selection continued for
72 hours post-transduction and completed upon the selection against the hTERT
RPE-1 parental line as a control. Completion of selection was considered the initial
timepoint (T0). The TKOv3-transduced cells were split into technical replicates. To
ensure proper coverage, 15 x 106 cells across 11 x 15 cm dishes were used for
infection with the TKOv3 virus per replicate. The chemotherapeutic drugs
Gemcitabine (2nM) and Vincristine (0.4nM) were added to separate replicates, with
one set of replicates receiving no drug treatment. Both drug-treated and untreated
replicates were not allowed to reach confluence in the 15cm dishes. Cells were lifted,
counted, and re-plated at the coverage stated above, and the excess cell pellets were
frozen at -20oC as a timepoint. Once 8 doublings were reached from T0, the screens
were terminated and pellets frozen at -20oC. Coverage of screens was kept at 200
cells per gRNA.

The QIAamp Blood Maxi Kit (Qiagen) was used to isolate the genomic DNA
(gDNA) from the frozen cell pellets. Guide sequences were enriched using PCR with
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HiFi HotStart ReadyMix (Kapa Biosystems) and primers targeting the guide region in
the genomic DNA. A second round of PCR was performed with i5 and i7 primers to
give each condition and replicate a unique multiplexing barcode. The final PCR
products were purified using the E-Gel System (Invitrogen), normalized, and
sequenced on the NextSeq500 system to determine the representation of guides
under each treated and non-treated condition.

2.4 Results and Discussion
We created the drugZ algorithm to fill a need for a method to identify
chemogenetic interactions in CRISPR KO screens. In a pooled library CRISPR
screen, the relative starting abundance of each gRNA in the pool is usually sampled
immediately after infection and selection. To identify genes whose KO results in a
fitness defect (“essential genes”), the cells are grown for several doublings and the
relative abundance of gRNA is again sampled by deep sequencing of a PCR product
amplified from genomic DNA template. The relative frequency of each gRNA is
compared to starting gRNA abundance, and genes whose targeting gRNA show
consistent dropout are considered essential genes.

In a chemogenetic interaction screen, the readout is different: the relative
abundance of gRNA in a treated population is compared to the relative abundance of
an untreated population at a matched time point (Figure 2.A). In this context, an
experimental design with paired samples should be particularly powerful, as it
removes a major source of variability across replicates.
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To benchmark the method, we evaluated screens to identify modifiers of the
response to the PARP inhibitor olaparib in three cell lines, RPE1-hTERT, HeLa, and
SUM149PT (Zimmermann et al., 2018). The screens were performed using the
TKOv1 library of 90k gRNA targeting 17,000 genes and are described in detail in
(Hart et al., 2015). After infection and selection, each cell line was split into 3
replicates, passaged at least once, and each replicate was further split into control
and olaparib-treated populations (Figure 2.A).

The drugZ algorithm calculates a fold change for each gRNA in an
experimental condition relative to an untreated control. A Z-score for each fold
change is calculated using an empirical Bayes estimate of the standard deviation, by
“borrowing” information from gRNA observed at a similar frequency (read count) in
the control cells. Guide-level gene scores are combined into a normalized genelevel Z-scores called normZ, from which P values are estimated from a normal
distribution (Figure 2.B). We used drugZ to calculate normZ scores, P values, and
false

discovery

rates

in

SUM149PT

breast

cancer

cells,

which

carry BRCA1 and TP53 mutations, +/− olaparib treatment (Zimmermann et al.,
2018). We also analyzed the same data with four contemporary methods, STARS
(Doench et al., 2016), MAGeCK (W. Li et al., 2014), edgeR (Robinson et al., 2010),
and RIGER (Luo et al., 2008). We noted that drugZ produced a moderate number of
overall hits, relative to other methods, as FDR thresholds were relaxed (Figure 2.C).
We evaluated the quality of the hits by measuring their functional coherence. The
PARP inhibitor olaparib was developed specifically to exploit the observed SL
relationship between PARP1 and the BRCA1/BRCA2 genes (Bryant et al., 2005;
Farmer et al., 2005). Subsequent studies have shown it to be effective against a
29

general deficiency in homologous recombination repair, known as HRD (Ashworth,
2008b). We therefore calculated the enrichment of each hit set for genes in the DNA
damage response (DDR) pathway as annotated in the Reactome database (Croft et
al., 2011) and found that drugZ hits show strong enrichment for DDR genes across a
range of FDR thresholds (Figure 2.D, E), while the other methods show consistently
lower enrichment. We observed similar trends in an olaparib screen in HeLa cells
(Figure 3.A) but less overall effect in hTERT-immortalized RPE1 wildtype epithelial
cells (Figure 3.B). The combination of larger sets of hits and greater enrichment for
expected results indicates that drugZ accurately and sensitively identifies
chemogenetic interactions.
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Figure 3. DrugZ vs. other methods with olaparib screens in HeLa (A) and RPE1 (B)
cells. Methods are colored as in Figure 2.1.C. DrugZ hits show strongest enrichment
for DDR genes across a range of FDR thresholds in these two screens as well but
less overall effect in RPE1 cells. Data from (Zimmermann et al., 2018). A) Left,
number of raw hits. Center, number of annotated DNA Damage Response (DDR)
genes in hits. Right, log P-values for DDR gene enrichment. B) Same panels as in
(A), for RPE1 screens.
The drugZ algorithm can also be used to identify suppressor interactions, that
is, genes whose perturbation reduces drug efficacy. While BRCA1 mutation is SL
with PARP1, subsequent mutation of TP53BP1 is associated with acquired
resistance to the PARP inhibitor (Jaspers et al., 2013). Drug-gene interactions
resulting

in

positive Z-scores

reflect

such

suppressor

interactions.

Indeed, TP53BP1 is the 8th-ranked suppressor interaction in BRCA1-deficient
SUM149PT cells, with a normZ score of 3.05. Similarly, newly described resistance
gene C20orf196, now called SHLD1 (Dev et al., 2018; Ghezraoui et al., 2018; Mirman
et al., 2018; Noordermeer et al., 2018), is the top-ranked suppressor.

2.4.1 Robustness to parameter choice and experimental design
To evaluate the robustness of the drugZ approach, we conducted sensitivity
analysis using data from the SUM149PT olaparib screen. The algorithm relies on two
major tunable parameters, window size for empirical Bayes variance estimation and
a monotone filter for the variance estimator (to ensure non-decreasing variance as
read count decreases). The window size represents the number of neighboring
gRNA, ranked by read count, to use to evaluate gRNA fold change variance. To
evaluate the effect of varying window size, we ran the drugZ pipeline with window
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sizes in five increments from 100 to 1000; neither the number of hits, number of DDRannotated hits, nor enrichment P value was affected by changing window size (Figure
4.A-C). We performed a similar analysis with and without enforcing the monotone
filter and discovered marginally improved performance in the SUM149PT olaparib
screen without enforcing monotonicity (Figure 4.D-F), but no such effect in Hela (T15)
olaparib screen (Figure 4.G-I). We therefore left the filter in place.
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Figure 4. DrugZ tunable parameters. A) DrugZ performance across different window
sizes for Empirical Bayes estimation of variance of guide-level fold changes. B) Left,
number of raw hits. C) Center, number of annotated DNA Damage Response (DDR)
genes in hits. Right, log P-values for DDR gene enrichment. D-F) DrugZ performance
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with correction that ensures monotonicity in the variance (M, red) vs. drugZ
performance with no correction that ensures monotonicity in the variance (NM, blue)
in SUM149PT olaparib screen (panels same as in first row). G-I) DrugZ performance
with correction that ensures monotonicity in the variance (red) vs. drugZ performance
with no correction that ensures monotonicity in the variance (blue) in HeLa olaparib
screen (panels same as in first two rows).

We also tested the drugZ pipeline against a more statistically thorough, but
computationally demanding, approach. After using the same empirical Bayes
approach to calculate a Z-score for each guide, we applied Gibbs sampling to
estimate the posterior distribution of fold changes for each gene (Figure 5.A). This
method, which we termed drugGS, yielded results that are virtually identical to drugZ
(Pearson correlation coefficient = 0.99; Figure 5.B) at ~ 50× the computational cost
(Figure 5.C). DrugGS is also available on github at https://github.com/hartlab/druggs.
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Figure 5. DrugZ vs. DrugGs. A) DrugGS Computational Pipeline. DrugGS
preprocessing steps are same as in the DrugZ for generating guide-level Z-scores.
After guide level Z-scores are obtained, they are used as a prior distribution to
generate gene-level scores using Gibbs sampling. The mean of generated sample of
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means is considered as new gene score. B) Comparison between drugGS (x-axis)
and drugZ (y-axis) gene scores shows high concordance between the two methods
(Pearson correlation coefficient = 0.99). C) Comparison between drugGS (top) and
drugZ (bottom) time and memory performance. DrugZ drastically outperforms
drugGS in terms of time and memory used.

2.4.2 Experimental design considerations
Highly effective CRISPR KO screens are done with a variety of experimental
designs, with varying numbers of replicates, degree of library coverage,
determination of endpoint, and whether intermediate time points are included (Aguirre
et al., 2016; Doench et al., 2016; Hart et al., 2015, 2017; Koike-Yusa et al., 2014;
Meyers et al., 2017; Ong et al., 2017; Shalem et al., 2014; Tzelepis et al., 2016; T.
Wang et al., 2014, 2017a). The olaparib drug-gene interaction screens described
here were performed in triplicate in 15-cm plates and passaged every 3 days, with
drug added at day 6 and samples collected for sequencing at each passage starting
at day 12 (Zimmermann et al., 2018). Using the optimized drugZ pipeline, we
evaluated each time point in the SUM149PT screens. The screen’s ability to resolve
specific DNA damage response genes increased steadily from day 12 to day 18
(Figure 6.A–C), highlighting the importance of low-dose drug treatment (e.g., LD20).
The extended timeframe for the experiment allows greater resolution of negative
selection hits as they disappear from the population over several doublings.
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Figure 6. Experimental design effects. A-C) DrugZ performance across different time
points for SUM149PT olaparib screen. A) Number of raw hits. B) Number of
annotated DNA damage response (DDR) genes in hits. C −log P values for DDR
gene

enrichment. D-F) DrugZ

performance

based

on

varying

number

of

replicates. D) Number of raw hits. E) Number of annotated DNA damage response
(DDR) genes in hits. F) −log P values for DDR gene enrichment. Rep1, 2, 3: all
combinations of one, two, or three replicates, ± s.d. Mean: comparing mean of drugtreated samples to the mean of control samples (unpaired approach).
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Nevertheless, the screens are still quite noisy, necessitating several replicates
for accurate assessment of drug-gene interactions. The experimental design of these
screens involved control and drug-treated samples for each replicate, facilitating a
paired-sample analysis across the three replicates (Figure 7.A). In contrast, an
unpaired design (Figure 7.A) requires comparing the means (or other aggregate
metric) of the treated and untreated arms. In our experience, a paired-sample
experimental design typically results in within-replicate samples clustering together
(Figure 7.B), suggesting a paired-sample analysis would be more sensitive. Pairedsample analysis of three replicates in the olaparib screen clearly outperforms one- or
two-replicate designs (Figure 6.B). Surprisingly, however, the paired-sample
approach does not appear to offer significant benefits over an unpaired approach:
when taking the mean fold change across experimental samples and comparing it to
the mean fold change across control samples (Figure 7.A), the results are nearly
identical to analysis of three paired samples (Figure 6.D–F). Indeed, treating samples
as paired or unpaired produced highly correlated results (rho> = 0.96) in all three
olaparib screens (Figure 7.C-E), and the functional enrichment analysis in
SUM149PT cells showed virtually no difference when performing paired-sample or
unpaired-sample analysis (Figure 7.F-H).
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Figure 7. Paired vs. non-paired approaches in three olaparib screens. A)
Experimental designs describing paired (top) and unpaired (bottom) experimental
design and analysis strategy for chemogenetic interaction screens. B) Clustering of
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gRNA-level fold changes across replicates shows that within-replicate samples
correlate more closely than samples with similar treatment. C) Correlation between
paired samples (control A – treated A, control B – treated B, etc.) vs. non-paired
(mean (control A, B, C) – mean (drug A, B, C.)) for SUM149PT olaparib screen (rho
= 0.98). D) Same as in (A) for HeLa olaparib screen (rho = 0.96). E) Same as in (A)
for RPE1 olaparib screen (rho = 0.98). F-H) Comparison between paired and nonpaired approaches across number of significant genes, DDR genes and normalized
p-values in SUM149PT olaparib screen.

2.4.3 A general-use algorithm for drug-gene interactions
To ensure that the drugZ algorithm is not overspecialized for the strong
chemogenetic profile of PARP inhibitors, we applied it to a separate set of drug
interaction screens in pancreatic cancer cell lines using the ERK1/2 inhibitor
SCH772984. Oncogenic mutations in KRAS drive constitutive signaling in the MAP
kinase pathway and are associated with proliferation and survival signals. Consistent
with

current

models

of RAS pathway

activation,

knockout

of

inhibitor

target MAPK1 has strong synthetic sick/lethal or negative interactions with ERK
inhibitor in two of the cell lines, MiaPaca and YAPC (FDR < 0.1; Figure 8.A–D). In the
third

cell

line,

HPAF-II,

the

top

synthetic

interactors

were

drug

transporter ABCG2 and MAPK3. Activity of this drug resistance gene may account
for this cell line’s resistance to ERK inhibition and the lack of other synthetic effectors
in this screen. Drug transporter ABCC4 is SL in MiaPaca cells, indicating multiple
routes of drug resistance for this molecule. Ubiquitin ligase adapter KEAP1 is among
the top suppressors of ERK inhibitor activity in three cell lines (Figure 8.A–
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D). KEAP1 loss of function was identified as a modulator of MAP kinase pathway
inhibitors in a panel of positive selection screens in multiple cell lines (Krall et al.,
2017), suggesting a context-dependent model for predicting ERK inhibitor activity
(Figure 8.E). Notably, the ERK inhibitor screens yielded a small number of discrete
synthetic and suppressor hits, in contrast with the PARP inhibitor screens, which
showed broad interaction across the HR pathway, confirming the general applicability
of drugZ in detecting drug-gene interactions.
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Figure 8. DrugZ effectiveness across diverse screens. A-D) DrugZ-calculated normZ
score is plotted vs. gene rank for SCH772984 screen in four KRAS pancreatic cancer
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cells cell lines. Synergistic/SL (red) and suppressor/resistance (blue) interactions at
FDR < 0.1. E) Network view of ERK inhibitor screens. Red, SL interactions. Blue,
suppressor interactions. F-H) Glioblastoma cell lines screened for chemogenetic
interactions with temozolomide (TMZ), as described in (MacLeod et al., 2019). I)
Pathway-level summary of modifiers of TMZ activity in glioblastoma cells. J) hTERTRPE1 cells screened for modifiers of vincristine. K) Experimental design of
CRISPRi/CRISPRa screens for modifiers of rigosertib, as described in (Jost et al.,
2017). L) DrugZ results of the combined rigosertib screens. Red/blue hits are
characterized in (Jost et al., 2017).
We additionally reanalyzed data from a set of temozolomide (TMZ) drug
modifier screens in patient-derived glioblastoma cell lines (MacLeod et al., 2019). The
screens clearly indicated SL with the Fanconi anemia complex (Figure 8.F) and
suppressor activity from the mismatch repair pathway (Figure 8.G-H). Together,
these results recapitulate the biological drivers of temozolomide: mismatch repair is
required for temozolomide cytotoxicity (J. Y. J. Wang & Edelmann, 2006), while the
Fanconi anemia pathway plays a major role in the repair of TMZ-induced damage
(Chen et al., 2007; Kondo et al., 2011; Yoshimoto et al., 2012) (Figure 8.I). We further
conducted an independent screen of hTERT immortalized RPE1 epithelial cells to
determine genetic modifiers of the microtubule stabilizing agent vincristine. Drug
transporter ABCC1 (encoding multidrug resistance protein-1, or MRP1), a known
marker for clinical resistance to vincristine (Cole et al., 1992; Godinot et al., n.d.), is
the top synthetic hit in our screen (Figure 8.J).

Finally, we reprocessed data from complementary CRISPRi/CRISPRa
screens for modifiers of rigosertib activity (Jost et al., 2017) (Figure 8.K). As
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transcriptional activation and repression are expected to show opposite effects in a
phenotypic screen, we plotted the drugZ results for the CRISPRi screen and the
CRISPRa screen together (Figure 8.L). The microtubule stabilizing activity
of TACC3 and destabilizing activity of KIF2C, characterized extensively in (Jost et al.,
2017),

are

both

recovered

by

drugZ,

along

with

tubulins TUBA1B and TUBB4 (Figure 8.L), consistent with rigosertib’s activity as a
microtubule destabilizing agent. Importantly, these results confirm the applicability of
drugZ beyond CRISPR KO screens.

We noted that a small number of genes were unexpected repeat hits across
several screens using a different drug or small molecule perturbagens with disparate
mechanisms of action. We screened hTERT-RPE1 cells with gemcitabine, a
pyrimidine nucleoside analog, and analysis with drugZ reveals a SL interaction with
deoxythymidylate kinase DTYMK. DTYMK phosphorylates dTMP to dTDP, a key
step in the synthesis-by-salvage pathway of dTTP (Arnér & Eriksson, 1995)
(Figure 9.A).

However,

suppressors

of

gemcitabine

activity

included NF2, TP53, AXIN1, and other known tumor suppressor genes (Figure 9.A)
with no known role in nucleotide metabolism. This immortalized epithelial cell line
carries wildtype alleles of these tumor suppressors, and their KO in a CRISPR screen
results in cell proliferation more rapid than wildtype cells. This is reflected in the
essentiality profiles, as calculated by BAGEL (Hart & Moffat, 2016): essential genes
have positive Bayes Factors, but tumor suppressors show extreme negative scores
(Figure 9.B).
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Figure 9. Tumor suppressor genes are frequent drug suppressor hits. A) normZ plot
hTERT-RPE1 screen for modifiers of gemcitabine activity, colored as in
Figure 8. B) Gene essentiality of untreated hTERT-RPE1 cells. Purple, essential
genes. Green, genes whose KO imparts a fitness advantage. C) normZ plot of A375
melanoma cell line screen for vemurafenib modifiers; data from (Shalem et al.,
2014). D) Gene essentiality scores for A375; data from (Behan et al., 2019).

We hypothesized that such tumor suppressors might be systematic,
nonspecific hits in drug-gene interaction screens. We re-analyzed other screens to
understand this behavior across different cell backgrounds. The landmark CRISPR
screen paper from Shalem et al. (Shalem et al., 2014) includes a screen in BRAF45

mutated A375 melanoma cells for resistance to vemurafenib and describes the
discovery of NF2 as a novel suppressor of vemurafenib activity. DrugZ analysis
confirms NF2 as a strong hit in the screen, along with NF1 and several members of
the mediator complex (Figure 9.C). Complementary analysis of the gene essentiality
profile for A375 derived from Behan et al. (Behan et al., 2019)—the latest screens
from the DepMap project are substantially superior to the first-generation screen
performed in Shalem et al., as shown by precision-recall analysis (Figure 10.)—
shows that NF2 is the top ranked tumor suppressor in the screen, and furthermore,
virtually every other vemurafenib suppressor hit shows enhanced cell fitness when
knocked out (Figure 9.D). Interestingly, we detect MCL1 and EGFR, as well
as EGFR signal transduction components SHC1 and GRB2, as SL with vemurafenib
in this screen. Neither hit is reported in the original study, but both MCL1 (Fofaria et
al., 2015) and EGFR (Prahallad et al., 2012; Sun et al., 2014) have been
characterized as routes of adaptive resistance to BRAF inhibition in melanoma.
These findings support the overall quality of the drug-gene interaction screen and our
analysis of the data. We further note that TP53 and CDKN1A (p21) are the top
suppressors in the RPE1 vincristine screen (Figure 8.J) and that TP53 is the top
suppressor in the G472 temozolomide screen (Figure 8.G). G472 cells carry a
wildtype p53 gene (MacLeod et al., 2019). Collectively these results indicate that
genes whose KO imparts a growth advantage on cells are recurrent hits in drug-gene
interaction screens, suggesting a drug-agnostic phenomenon rather than drugspecific resistance mechanisms.
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2.5 Conclusions
Identifying the genetic drivers of drug effectiveness and resistance is critical to
realize the promise of personalized medicine. Chemogenetic interaction screens in
mammalian cells using CRISPR KO libraries have so far been primarily used in a
positive selection format to identify the genes, pathways, and mechanisms of
acquired resistance to chemotherapeutic drugs. However, negative selection screens
to identify the underlying architecture of drug-gene interactions have been difficult to
carry out and to analyze in part due to the lack of robust analytical tools.

We describe the drugZ algorithm, which calculates a gene-level Z-score for
pooled library CRISPR drug-gene interaction screens. By taking into account the
moderate SMF defects associated with many genes involved in drug-gene
interactions, the drugZ algorithm offers significantly improved sensitivity over
contemporary analysis platforms. The algorithm was developed to exploit the
additional resolving power we expected to gain from a paired-sample experimental
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design, but surprisingly this has virtually no effect on our results. We demonstrate the
validity of our hits by showing the strong enrichment for genes involved in the DNA
damage response in a screen for interactions with the PARP inhibitor olaparib and
the precise detection of MAPK pathway effectors in an ERK inhibitor screen. We
further show that both synergistic and suppressor interactions can be identified in the
same screen, as the previously identified PARP resistance gene TP53BP1 and newly
characterized SHLD1(formerly C20orf196) are top-ranked suppressors of olaparib
activity

in BRCA1-mutant

SUM149PT

screens.

Moreover,

both

synthetic

targets MAPK1/3 and suppressor gene KEAP1are identified in ERK inhibition
screens. KEAP1 deletion or mutation is frequently found in KRAS-driven lung
adenocarcinomas and may present an obstacle to ERK inhibitor therapy in these
tumors.

Experimental design plays a critical role in the ability to accurately identify
drug-gene interactions. Negative selection screens for SL interactions require that
cells be carried long enough for dropouts—typically growth defects rather than full
synthetic lethals—to rise to statistical significance. Our results, concordant with
known highly drug-specific differences in effect timing, suggest that there is value in
collecting multiple time points to ensure that drug activity and genetic interaction are
detectable and that traditional dose-response curves must be calculated over a time
course relevant to the screen (e.g., at least two passages or several doublings).

Copy number amplifications have been widely shown to cause locus-specific,
but not gene-specific, toxicity in CRISPR KO experiments. This phenomenon can
lead to false positives in screens for KO fitness defects. However, drug-gene
48

interaction screens measure whether, in the CRISPRko case, a double-strand break
at a specific locus amplifies or suppresses the activity of a small molecule or other
perturbagen. Amplification-specific artifacts should, in principle, show no difference
between treated and control samples and should therefore not be a significant source
of false positives. However, gRNA targeting amplified loci may rapidly drop out of a
population of cells under library-induced selection; the absence of these loci at
experimental end points (as measured by gRNA read counts) could feasibly mask
the detection of drug-gene interactions, resulting in false negatives.

Despite these technical idiosyncrasies, chemogenetic interaction screens
extend the utility of CRISPR genome-scale perturbation screens by enabling the
systematic survey of the landscape of drug-gene interactions across cancer-relevant
genetic backgrounds. Understanding this variation may lead to more precise
therapies for patients as well as the development of synergistic drug combinations for
genotype-specific treatments.

2.6 Availability of data and materials
Project name: drugz
Project home page: https://github.com/hart-lab/drugz
Operating system: platform independent
Programming language: Python
Other requirements: Python v3.7 or higher; modules numpy, scipy, pandas.
License: MIT
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No restriction for non-academic use
All software described in this manuscript, as well as all data files used for analysis,
are available (under the MIT license) at the Hart Lab github site and figshare:

https://github.com/hart-lab/drugz
https://github.com/hart-lab/druggs
https://figshare.com/projects/DrugZ_software_from_the_Hart_Lab/65582

2.7 DrugZ web-based user interface
In addition to the above-described software, I have created a complementing
user-friendly interface. This application was inspired by a wide use of drugZ algorithm
(>10000 article accesses and ~50 citations in the past two years). Even though the
use of drugZ is simple (tutorial on how to use it provided in the github repository linked
above), some of the users experienced difficulties such as setting up the virtual
environment, modules/packages versions’ discrepancy, unfit input files, etc.
Therefore, the goal of web-based drugZ application is alleviate some of these
difficulties and make the use of drugZ even more accessible. The application is
available on https://drugz.hart-lab.org.

DrugZ application is based on the Dash Enterprise, which is an open-source
python framework created by Plotly for creating interactive web applications
(https://plotly.com/dash/). The application layout is composed of three divisions or
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containers (Figure 11.): title and the purpose of software, user input and parameters,
and analysis results. The first step for users is to upload their file, after which they will

get a confirmation message for a successful upload if the file is satisfying the criteria
that the rows are unique guides, columns are different samples, and values are the
raw read counts of a guide construct. The next step is to select the comparison
approach for comparing the guide abundance between the control and treatment
samples. The two approach types, unpaired and paired, are characterized above
(Figure 7.A). This is followed with selecting control and treatment samples. Lastly,
users can specify the size of sliding window used to estimate the empirical Bayes
variance. Once all parameters are specified, users can initiate the analysis with the
‘Run’ button. After analysis is completed, users can download the results as a tab
separated file by clicking on “Download results” button, and as scatter plot with the
highlighted hits under FDR<0.1 threshold (Figure 12.).
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Figure 11. DrugZ dash application with outlined divisions.

Figure 12. Example of downloadable results of drugZ analysis.
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Chapter 3: Predicting synthetic lethality

3.1 Background
3.1.1 First observations of genetic interaction phenomenon
The term epistasis was defined by William Bateson over a hundred years ago,
inspired by the observation that genes frequently interact with one another, distorting
simple Mendelian ratios and sometimes leading to novel phenotypes. Even before
the official term was coined, the phenomenon of gene interaction was observed in
the chicken combs study conducted by Bateson and Punnet (Bateson & Punnett,
1905). They noticed that the single comb type was produced less frequently than the
other comb types in their cross experiments and was difficult to accommodate with
the simple Mendelian genetic system, which is based on a belief that a trait or a gene
acts independently in its actions in an individual's genome (Castle, 1903; Mendel,
n.d.). Using Punnet square, which describes all possible combinations of gametes,
they concluded that comb inheritance could be described by Mendelian law of
segregation and that the single comb phenotype appears only in the rare doublerecessive homozygotes. Even though Bateson coined the term which describes this
phenomenon, there has been very little use of the word epistasis in the first few
decades of the 20th century, even by Punnet and others close to Bateson and
Mendelian segregation (Phillips, 1998). However, in the second half of the century,
the concept of epistasis and its analysis made a comeback not only as a description
of segregation ratios but also as the analysis of gene function and means of decoding
genetic systems (Phillips, 2008).
Mendelian and Biometrical schools of genetics had different definitions of
epistasis (Phillips, 1998) until R. A. Fisher showed analytically that the Mendelian
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segregation was compatible with the Biometrician laws of heredity (Fisher, 1918),
establishing the field of quantitative genetics. After noticing that the reason for a
difference between Mendelian and statistical formulations of epistasis was the
limitations in language for describing gene interactions, and that simply detecting
interaction and giving it a general name is insufficient for it to be broadly used and
applicable,

the

classification

of

genetic

interactions

and

corresponding

characterizations started appearing (Fenster et al., 1997; Whitlock et al., 1995).
For example, SL interactions, despite the thought that they could be too rare
to be significant (Temin et al., 1968), nowadays are widely studied and of great
interest for therapeutical purposes in oncology. Synthetic lethality is a phenotype first
observed in Drosophila when two (or more) genes taken separately are not lethal to
homozygotes but become lethal when combined by crossing over (Bridges, 1944;
Dobzhansky, 1946). In a cellular context, SL interactions are genetic events in which
the deletion/change of both genes leads to a cell lethality, whereas deletion of one of
these genes results in cell viability. The rest of this chapter will focus on SL
interactions in cultured human cells.

3.1.2. Genetic interactions networks
Genetic interactions refer to the unexpected phenotype or a phenotype
deviated from the expected phenotype defined as a combination of individual
mutations. In addition to providing insights about gene functions, genetic interactions
are thought to underlie diverse aspects of biology, including the evolution of sex,
speciation, complex diseases (Altshuler et al., 2008; Phillips et al., 2000) and were
shown to play an important role in understanding the hereditability (Phillips, 2008).
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The advent of high-throughput genetic screening and the systems biology
approaches reinvigorated genetic interactions in a more quantitative manner, leading
to the mapping of genetic interaction networks, which were/are instrumental for
explaining and understanding the modularity of a cell (Baryshnikova et al., 2013;
Beltrao et al., 2010; Boucher & Jenna, 2013; Costanzo et al., 2019; Domingo et al.,
2019; Mair, Moffat, et al., 2019). The biggest limitation for a systematic studying of
genetic interactions is the scale. Given an n number of genes in a genome, to
examine all possible genetic interactions between every gene pair, means the total
number of genetic interactions is n * (n-1). If the reciprocal pairs are omitted, then the
total number of interactions is (n * (n-1))/2. Therefore, it becomes an extreme task to
test all interactions when we are looking at a genome with thousands of genes. For
example, a yeast genome with ~6000 genes equates to ~18 million genetic
interactions and a human genome with ~18000 genes means ~180 million
interactions (ignoring the reciprocal pairs). The most comprehensive studies of
mapping genetic interactions network were first done in the Saccharomyces
cerevisiae yeast model system (Costanzo et al., 2010a, 2016, 2019) using either
genome-wide collections of defined mutants of gene perturbation systems (e.g.
synthetic genetic arrays). This work revealed functional map of the cell in which genes
with similar genetic interaction profiles cluster together, and was seminal for
understanding genetic interactions, and functional modules. Similar efforts were
applied to Drosophila cells (Fischer et al., 2015) and Schizosaccharomyces pombe
yeast (Roguev et al., 2007). However, translating these undertakings into human cells
is not a direct approach. When assembling the functional map of a yeast cell genetic
interaction profiles were used to infer functional interactions, whereas in such studies
in human cells these networks are built from gene fitness profiles. Assaying digenic
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perturbations in human cells is not scalable on a genome-wide level even with the
CRISPR technology, which offers the most robust and scalable method for gene
editing in human cells. Therefore, few groups including us in Hart lab have used
indirect methods (Boyle et al., 2018; E. Kim et al., 2019a; Rauscher et al., 2018;
Wainberg et al., 2021; T. Wang et al., 2017b) to derive functional interactions from
publicly available CRISPR KO screens data from nearly ~1000 cancer cell lines
(Broad Institute, 2019; Sanger Institute, 2019). These methods have been
instrumental in expanding our knowledge about biological processes, pathways and
functional modules making the hierarchical assembly of a cell. But these approaches
do not provide direct information about genetic interactions in human cells.

3.1.3 Combinatorial CRISPR screens
Genetic interactions in human cells were exploited with CRISPR combinatorial
screens in the last decade as well. This was facilitated using CRISPR systems with
two Cas9 nucleases and two promoters (e.g., hU6 and mU6), in which case each
guide has an independent association, therefore avoiding unequal targeting.
Additionally, there are other systems such as single Cas9 with two copies of same
promoter, or a single Cas9 with two different promoters (competitive association). The
most current multiplex screening is based on enCas12a platform, whose major
advantage over Cas9-based multiplex systems is that a guide pair can be synthesized
in a single construct, allowing one-step library design. The research produced by
these multiplex targeting systems has shown potential to identify context-specific
genetic interactions, candidate combinatorial drug treatments and potential drug
targets (Boettcher et al., 2018; Dede et al., 2020; DeWeirdt et al., 2019, 2020; Diehl

56

et al., 2021; Han et al., 2017; Horlbeck et al., 2018; Ito et al., 2021; Lenoir et al., 2021;
Najm et al., 2018; Parrish et al., 2020; Shen et al., 2017, 2017; Thompson et al.,
2021; Wong et al., 2016). However, the gold standard rules around scoring and
characterizing genetic interactions are still lacking. The most interesting and widely
studied genetic interactions are SL interactions. These are interactions in which the
deletion/change of both genes leads to cellular or organismal death, whereas a
deletion of one of these genes does not. However, when we looked at few of these
CRISPR-mediated genetic interactions studies (Table 3.1), we noticed that very few
SL interactions have been reproduced across multiple studies and many appear
highly context specific. Moreover, even when it comes to the intersection of tested
pairs across these different studies, there are not many gene pairs that have been
tested in more than two studies (Figure 3.1). Hence, the major drawback is the lack
of gold standards SLIs, and a baseline probability of being a GI for every gene pair.
Study

Background

Han et al. 2017

K562

Najm et al. 2018

Target

Screening platform

207 genes

Combinatorial Cas9 KO

drug targets

(mU6 + hU6)

A549, A375, Meljuso,

158 genes

Orthogonal Cas9 KO

7860, OVCAR8

apoptosis and DDR

(S. aureus + S. pyogenes)

472 genes

Horlbeck et al. 2018

K562, Jurkat

Aregger et al. 2020

HAP1

Pournatzis et al. 2020

HAP1, RPE1

672 paralogue pairs

Cas9 + Cas12a KO

Dede et al. 2020

A549, HT29, OVCAR8

403 paralogue pairs

enCas12a multiplexing

Lenoir et al. 2021

MOLM13, NOMO1

Doench lab unpublished

A375, OVCAR8

moderate fitness defect
6 query genes (lipid
metabolism) vs. all

8 query (lipid metabolism)
vs. 100 array genes
20 apoptotic genes
50 DDR genes

Cas9 KO + CRISPRi

Cas9 KO isogenic screens

enCas12a multiplexing

enCas12a multiplexing
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Table 1. Selected existing studies of CRISPR-based genetic interactions in human
cells used in the training process.

Figure 13. Intersection of tested pairs across selected existing CRISPR-based
genetic interactions studies. Horizontal bars on the left indicate the size of a set, while
the vertical bars on top represent the intersection size. For most intersections the
number of overlapping tested pairs is below 10, whereas intersections between
Horlbeck et al. and Han et al., Njam et al. and Han et al., Dede et al. and Pournatzis
et al. have 35, 41, and 61 overlapping pairs, respectively.

The rest of this chapter will focus on describing the computational approach I
am proposing to address the mentioned drawback. Probabilistic prediction of
synthetic lethality uses Bayes theorem to make predictions and is trained on data
from existing CRISPR-based genetic interaction screens (prior information) and other
functional genomics data derived from essentiality, expression, protein, and genomic
neighborhood concepts (conditional information).
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3.2 Methods
3.2.1 Collecting and combing data from existing CRISPR-mediated genetic
interactions screens
The first step was to collect the data from CRISPR-mediated genetic
interaction screens (Table 1.). The thing that made this difficult was the fact that
almost every study had a different method for scoring genetic interactions making it
more challenging for unanimous hit calling (Table 2., Figure 15.A).
Study

Scoring method

Han et al. 2017

Normalizing residual effects to control guide phenotypes, as well as
to the phenotypes of similar guides using a moving average across bins

Najm et al. 2018

dLFC = observed - expected

Horlbeck et al. 2018

Quadratic fit between single and double KO phenotypes

Aregger et al. 2020

LOESS regression between WT and KO screen pairs

Pournatzis et al. 2020

Guide orientation-based scoring between observed
and expected KO phenotypes

Dede et al. 2020

dLFC = observed - expected

Lenoir et al. 2021

Linear regression fit between the single
and double KO phenotypes

Doench lab unpublished

dLFC = observed - expected

Table 2. Scoring methods for genetic interactions used in the studies in Table 1.
In yeast genetic interactions studies, genetic interactions are quantified as a
difference between observed and expected DMF, where expected DMF is product of
SMFs. Applying this this scoring approach to genetic interactions generated through
CRISPR screens means operating in log2 fold change (LFC) space, which is the
fitness quantification from CRISPR screens (Figure 14.). Therefore, SMF is the mean
LFC of control guides targeting a single gene, expected DMF is the sum of two SMFs,
and observed DMF is the mean log fold change of dual-targeting constructs. Delta
log fold change (dLFC) is the difference between observed and expected LFC and is
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used as a final genetic interaction score. To combine the data from previously
mentioned studies (Table 3.1), We collected their raw data from original publications
(Aregger et al., 2020; Dede et al., 2020; Gonatopoulos-Pournatzis et al., 2020; Han
et al., 2017; Horlbeck et al., 2018; Lenoir et al., 2021; Najm et al., 2018) and applied
dLFC as a genetic interaction scoring method for unanimous hit definition (Figure
15.B). To normalize these scores even further and place them onto same scale, dLFC
scores were converted to Z score (Figure 15.C), by truncating the top and bottom
2.5% of dLFC scores. After normalization and transformation, we ended up with
~200000 gene pairs, which then were grouped based on the empirical rule of two
standard deviations (std), where 95% of data falls within two std from the mean z
score dLFC, and 5% outside of it, 2.5% in both positive and negative directions
(Figure 16.). As mentioned earlier, the interactions of interests in this project are
negative or SL interactions, so the following steps and predictions are based only on
these two groups: the negative and no interaction groups.

Figure 14. Scoring genetic interactions as a
difference (dLFC) between observed and
expected DMFs. SMF is the mean log fold
change of control guides targeting a single
gene. Expected DMF is the sum of SMFs.
Observed DMF is the mean log fold change of
guide pairs targeting gene pair of interest.
Depicted above is an example of SL
interaction scored with the dLFC method.
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Figure 15. Genetic interactions Scores. A) Scores calculated using the methods
presented in the original studies (Aregger et al., 2020; Han et al., 2017; Horlbeck et
al., 2018; Lenoir et al., 2021). B) Genetic interaction scores produced with the dLFC
method. C) Z-score transformation of dLFC scores.

Figure 16. Grouping of genetic interactions in the training set. After aggregating
interactions from the different studies there were grouped into three groups based on
the z-score’s distribution layout: 1) negative or SL interactions group (blue), to the left
of mean – (2 * standard deviation), 2) no interaction group (grey), within the 2
standard deviations from the mean on both side, and 3) positive interactions group
(orange), to the right of mean + (2 * standard deviation). The bars and points in
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boxplot are colored based on these three groups. The positive interactions group is
not used in the further analysis.

3.2.2 Other functional data types
Conditional information which is integrated with the processed and normalized
genetic interactions scores comes from four categories, or genetic concepts,
essentiality, expression, protein or genomic location neighborhood and sequence
dependent features. In total, thirty features are collected from publicly available
databases and studies, and some are calculated from existing feature or combination
of features (Table 3.).
Category

Essentiality

Expression

Protein and
genomics
neighborhood

Features (n = 30)

Source

Coessentiality

DepMap

Number of total coessentiality interactors

Coessentiality

Number of shared coessentiality interactors

Mean BF score for shared coessentiality interactors

Coessentiality
Coessentiality and
DepMap
Coessentiality and
DepMap
Coessentiality and
DepMap

Coexpression

CCLE database

Number of total coexpression interactors

Coexpression

Number of shared coexpression interactors

Mean BF score for shared coexpression interactors

Coexpression
Coexpression and
DepMap
Coexpression and
DepMap
Coexpression and
DepMap

STRING; protein-protein interactions

STRING database

Number of total protein-protein interactors

PPIs

Number of shared protein-protein interactors

PPIs

Mean essentiality of shared protein-protein interactors
Percent of shared protein-protein interactors essential in
90% cell lines (DepMap)

PPIs and DepMap

Mean BF score for shared protein-protein interactors

PPIs and DepMap

Mean essentiality of shared coessentiality interactors
Percent of shared coessentiality interactors essential in 90%
cell lines (DepMap)

Mean essentiality of shared coexpression interactors
Percent of shared coexpression interactors essential in 90%
cell lines (DepMap)

PPIs and DepMap
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DNA
sequence

huMap - protein complexes

Drew et al. 2021

HuRI - binary interactome
HumanNet - functional gene network

Luck et al. 2020
C. Y. Kim et al.
2021

Colocalization

Thul et al. 2017

Shared GO terms

GO database

Shared chromosome

Ensembl

Shared strand

Ensembl

Shared family

Ensembl

Shared domains

Ensembl

Percent sequence identity

Ensembl

Mean GC content

Ensembl

Mean age

Ensembl

Table 3. Features acquired from four genetic concepts. Features’ categories,
descriptions, and sources from which they were obtained are provided in the
corresponding columns.

Essentiality concept
Essentiality is a fundamental genetic concept, aiming to identify and
characterize genes that are necessary for the survival of an organism. In this study
our focus is on human cells as a model system, therefore essentiality concept in this
instance aims to characterize genes indispensable for cellular viability and
proliferation. Similarly, coessentiality, which is one of the features used, is defined as
similarity, quantified by Pearson correlation coefficient (PCC), between the fitness or
essentiality profiles of two genes across a multitude of molecular contexts. The same
approach as described in the previous study from our lab defining the coessentiality
concept by Kim et al. (E. Kim et al., 2019b) was used to acquire the coessentiality for
all gene pairs across ~800 CRISPR-Cas9 KO screens carried in human cancer cell
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lines. Raw read counts data and relevant mapping files such as cross reference of
guides to genes, replicates to cell lines, and cell line information were obtained from
the DepMap database (https://depmap.org/portal/, AVANA 2020Q2) (Broad Institute,
2019; Sanger Institute, 2019). Next, we filtered out the data and kept only the proteincoding genes, annotated using HUGO Gene Nomenclature Committee (HGNC)
(Tweedie et al., 2021) and Consensus coding sequence database (CCDS) (Pujar et
al., 2018). sgRNAs targeting multiple genes were discarded as well to avoid the
correlated variation between fitness profiles driven by the depletion of the same
sgRNA. Filtered read counts were then subjected to unsupervised copy number
correction of gene-independent responses via CRISPRcleanR (Iorio et al., 2018)
algorithm, which also calculates sgRNAs log2 fold change. The resulting log2 fold
changes are processed with our BAGELv2 (E. Kim & Hart, 2021) algorithm to
calculate an essentiality score for each genes. After essentiality classification, we end
up with a matrix where columns are cell lines, rows are genes, and values are Bayes
factors (BFs) of essentiality scores, where negative BF demonstrates non-essential
genes and positive BF indicates essential genes. Ultimately, we calculate the
pairwise Pearson correlation of KO fitness profiles resulting in a list of gene pairs and
corresponding PCCs or coessentiality scores. Additionally, few other features were
derived from coessentiality and AVANA dataset (Table 3. Category: Essentiality).
Number of total interactors is the union of all gene1 and gene2 coessentiality
interactors, where a coessentiality interaction is instance where gene pair has a
coessentiality PCC > 0.3. Similarly, the number of shared interactors is the number
of genes that have a coessentiality interaction (PCC > 0.3) with both gene1 and
gene2, or an intersection of gene1 and gene2 interactors. Mean essentiality of shared
coessentiality interactors, where essentiality for each interactor is calculated as the
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percentage of cell lines (in AVANA dataset from DepMap, in which it is essential (BF
> 10). Percent of shared coessentiality interactors essential in 90% cell lines
(DepMap) and mean BF score for shared coessentiality interactors were also used
as functional similarity features. The features calculated from coessentiality and
DepMap data were inspired by the Kegel et al. work (De Kegel et al., 2021), in which
they exploit a set of similar features to predict synthetic lethality between paralog
pairs in cancer cell lines.

Expression concept
Gene expression is a regulated process by which the gene information is
converted into a functional product, or a protein. The TPM RNAseq expression data
for the same set of cell lines as in DepMap AVANA dataset was obtained from Cancer
cell line encyclopedia (CCLE) database (https://sites.broadinstitute.org/ccle/).
Expression based features; coexpression, number of total and shared coexpression
interactors, mean essentiality of shared coexpression interactors, percent of shared
coexpression interactors, percent of shared coexpression interactors in 90% cell
lines, and mean BF score for shared coexpression interactors were calculated using
the same processes and thresholds as in the above-described essentiality-based
features.

Protein and genomic neighborhood
Protein-protein interactions (PPIs) capture physical connections between gene
products, and as such are relevant for mapping the network of cellular functions
(VanderSluis et al., 2018), have been shown as successful predictors of both yeast
and human genetic interactions (De Kegel et al., 2021; Lord et al., 2020; Madhukar
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et al., 2015). PPIs and corresponding confidence scores were obtained from the
STRING database (Szklarczyk et al., 2021). These confidence scores are not the
quantification of the strength or the specific of an interaction, rather they are
measurement of how likely the STRING interprets an interaction as a true PPI given
the evidence. The confidence scores range from 0 to 1, where 1 is the highest
confidence. The score of 0.4, which is defined as medium confidence score by the
STRING, was used to binarize the PPIs data and generate other features as in
essentiality and expression concepts (number of total and shared protein-protein
interactors, mean essentiality of shared protein-protein interactors, percent of shared
protein-protein interactors, percent of shared protein-protein interactors in 90% cell
lines, and mean BF score for shared protein-protein interactors). Additionally, the
reference map of the human binary protein interactome (HuRI) (Luck et al., 2020),
and the map of human protein complexes (huMap) (Drew et al., 2021) were used as
features characterizing PPIs and protein complexes. Given the fact that genetic
interactions were used to infer functional interactions in yeast (Costanzo et al., 2010a,
2016, 2019), probabilistic network of functional interactions in human (C. Y. Kim et
al., 2022, p. 3) was used as another feature that could be a predictor of genetic
interactions in human.
In addition to protein neighborhood-based features, we have utilized few
features stemming from genomic neighborhood or location: colocalization (Thul et al.,
2017), shared chromosome, shared strand, and shared gene ontology (GO) terms –
indicating whether both genes in a gene pair share subcellular locations,
chromosome, strand, and GO terms. Chromosome and strain features were obtained
from Ensembl database (https://useast.ensembl.org/index.html). GO terms for each
gene were collected from GO database (http://geneontology.org), and to determine
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whether the genes in a pair have any terms in common we looked at the intersection
of two genes’ terms.

Sequence concept
Features in sequence category were obtained from Ensembl database. Mean
age was calculated as a mean of gene1 and gene2, two genes forming a gene pair.
Similarly, mean genomics GC content was calculated as a mean of GC contents from
gene1 and gene2. Percent sequence identity refers to a quantitative measurement of
the similarity between the DNA sequences of two genes. Two other features that
measure sequence-based similarities are shared gene family and shared domains,
that is whether genes in a gene pair belong to the same gene family and if they have
a shared domain(s).
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Figure 17. Distributions of continuous features. Shown are distributions for 24
continuous features, where color coding is based on feature’s category, and hatching
is indicative of genetic interaction groups.
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3.2.3 Encoding the features
The set of acquired features consists of 6 binary and 24 continuous features
(Figure 17.). The expectation was to see the difference in distribution between the
two genetic interaction groups, no interactions and negative or SL interactions
groups. However, for most features there is no significant difference or trend between
the two genetic interaction groups. To make these continuous features simpler and
model friendly we have utilized four encoding approaches to either binarize the
features or bin their values (Figure 18.). Mean GC content, number of total, and
number of shared coessentiality, coexpression, and protein-protein interactions, were
encoded using the intersection of two distributions defined by genetic interaction
groups as a threshold for binarizing the values. For features which had bimodal or
multimodal distributions (percent of shared coessentiality, coexpression, and proteinprotein interactors essential in 90% of AVANA cell lines, mean essentiality of shared
coessentiality, coexpression, and protein-protein interactors, mean age, and
sequence identity), the minima of those distributions were used as a threshold for
binarizing the values of those features. For coessentiality and coexpression features,
we sorted the values in a descending order, and organized the values into equalsized bins. The mean of values in each bin was used as a final quantification of that
bin. Therefore, coessentiality and coexpression features are transformed into 20 bins,
where each bin had a unique value. Finally, the fourth encoding approach is based
on literature-defined thresholds, for example BF = 10 was used to defined
essentiality, a threshold defined by our lab and widely used by other groups in the
fields, and confidence score = 0.4 for PPIs, defined by STRING databased as a
medium confidence level, meaning that pairs with confidence scores => 0.4 were
considered a true PPI.
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Figure 18. Encoding approaches. The four approaches used to encode the features
are 1) intersection of two distributions (genetic interactions groups), 2) minima of
bi/multimodal distributions, and 3) literature-based threshold are used as thresholds
for binarizing features’ values, lastly 4) sorting the values in descending order,
organizing them in equal-sized bins and assign the mean of the values in a bin as a
representative value of that bin, meaning that each bin would in the end have one
value. Under each approach, features which were subjected to it are indicated.
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3.2.4 Odds ratios (ORs) and likelihood
After feature processing and transforming, the next step was to quantify the
predictive power of each feature using the odds ratio. For every feature we create
equivalent to confusion matrix (Table 4.) from which we calculate the log2 of odds
ratio (LOR) (Equation 1.), which is the log2 ratio of feature’s probabilities given the
group of genetic interaction: no interaction or negative interaction / synthetic lethal.
For a feature whose values were organized into bins, LOR score is calculated for
each bin, whereas binary features have only one LOR score. The LORs for all
features are aggregated to quantify the overall likelihood (Equation 2.) for a gene pair
belonging to one of the genetic interaction groups.
Feature yes

Feature no

Negative of SL interaction (GI yes)

a

b

No interaction (GI no)

c

d

Table 4. Matrix for calculating feature's LOR. Feature yes is the number of
instances/pairs for which there is a value of that features characterizing that pair.
Feature no, is difference between the number of all observations/pairs and feature
yes numbers. A is the number of pairs that are negative interaction and for which we
have additional support from the feature, B is the number of negative interaction pairs
for which there is no additional support from the feature, C is the number of pairs with
no interaction for which there is additional knowledge from the feature, and lastly, D
is the number of no interaction pairs with no knowledge from the feature.

Equation 1. 𝐹𝑒𝑎𝑡𝑢𝑟𝑒 𝐿𝑂𝑅 = log 2 (

𝑃(𝐹 |𝐺𝐼𝑦𝑒𝑠 )
𝑃(𝐹 |𝐺𝐼𝑛𝑜 )

𝑎

) = log 2 ( 𝑎+𝑏
𝑐 )
𝑐+𝑑

Equation 2. 𝐿𝑖𝑘𝑒𝑙𝑖ℎ𝑜𝑜𝑑 = ∑30
𝑖=1 𝑓𝑒𝑎𝑡𝑢𝑟𝑒 𝐿𝑂𝑅𝑖
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Equation 3. 𝑃𝑟𝑖𝑜𝑟 𝐿𝑂𝑅 = log 2 (𝐺𝐼

𝐺𝐼𝑦𝑒𝑠

𝑦𝑒𝑠 +𝐺𝐼𝑛𝑜

)

Equation 4. 𝑃𝑜𝑠𝑡𝑒𝑟𝑖𝑜𝑟 𝐿𝑂𝑅 = 𝑃𝑟𝑖𝑜𝑟 𝐿𝑂𝑅 + 𝐿𝑖𝑘𝑒𝑙𝑖ℎ𝑜𝑜𝑑
2𝑃𝑜𝑠𝑡𝑒𝑟𝑖𝑜𝑟 𝐿𝑂𝑅
𝑃𝑜𝑠𝑡𝑒𝑟𝑖𝑜𝑟 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =
(1 + 2𝑃𝑜𝑠𝑡𝑒𝑟𝑖𝑜𝑟 𝐿𝑂𝑅 )

3.2.5 Bayes theorem-based prediction of synthetic lethality
The synthetic lethality predictions are based on the Bayes theorem which
states that the posterior probability of a random event or an uncertain proposition is
the conditional probability given the relevant evidence or background. Similarly, in
the logarithmic space, posterior odds ratio is the sum of likelihood and prior odds
ratio. Prior odds ratio or prior probability represents quantification of knowledge about
a data object or an observation before some further evidence is considered. Prior
odds ratio of a gene pair having a SL interaction is calculated as log2 of the ratio of
two between negative or SL interactions (defined by a z-score threshold) and all
interactions used in the model training (interactions in both groups, SL and no
interaction groups) (Equation 3.). Given the likelihood (Equation 2.) and prior odds
ratio we calculated the posterior odds ratio and posterior probability (Equation 4.) on
a gene pair level. The magnitude of difference between posterior odds ratio and
probability distributions of two genetic interaction groups was quantified with t-test pvalue and Cohen-d statistics (Figure 19.) (used function: sklearn.stats.ttest_indv,
Scipy Python library). The smaller the p-value and the greater the Cohen-d the
greater the magnitude of difference between two groups.
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Figure 19. Distributions of posterior odds ratios and probability. Box plots are color
coded based on genetic interactions groups, no interactions and SL(SL) interactions.
The statistics (p-values and cohen-d values) is based on the independent samples.

3.2.6 Cross-validation
To avoid overfitting, we utilized the k-folds cross-validation method to partition
the

available

data

into

train

and

test

sets.

Function

sklearn.model_selection.cross_val_score(cv=5) was used. The ‘cv’ parameter
determines the cross-validation splitting strategy, meaning it split the dataset into k
(5 in our case) consecutive folds (without shuffling by default). Each fold is then used
once as a test set while the k - 1 remaining folds are used as the training set.

3.2.7 Feature importance and selection methods
Quasi-constant features
Quasi-constant features are the features that are almost constant. These fe
atures have the same values for a very large subset of the outputs, therefore wouldn
’t be very useful for making predictions, because they don’t offer sufficient variance.
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When it comes the variance of quasi-constant features, the rule of thumb is to remov
e features that have more than 99% similar values for the output observations. The r
emoval of quasi-constant features was done using sklearn.feature_selection.Varianc
eTreshold(threshold=0.01) function. The ‘threshold’ parameter of 0.01 means that if t
he variance of the values in a column is less than 0.01, remove that column. The fea
tures which had a variance greater than 0.01, and therefore were removed from the
Naïve Bayes model are HuRI - binary interactome, Colocalization, Percent sequenc
e identity, HumanNet - functional gene network, Shared family, Shared domains, Me
an age, Shared chromosome, Shared strand, Number of shared_coexpresion intera
ctors, Percent of shared protein-protein interactors essential in 90% cell lines (AVAN
A), Mean BF score for shared protein-protein interactors, and Mean BF score for sh
ared coessentiality interactors.

Shapley additive explanations (SHAP) method
Shapley value is a concept stemming from the game theory (S. Lundberg &
Lee, 2017; S. M. Lundberg et al., 2020). In a game, two or more players work togeth
er to achieve a goal. They each do their part, like a team. The Shapley value is the a
verage expected contribution of a player after all possible combinations have been c
onsidered. Say there are two players in the game. They each have a role to play, an
d they each can contribute to the outcome. The Shapley value helps to determine ho
w much each player gets paid for contributing to the outcome, or what the outcome i
s. Therefore, applying Shapley values towards interpreting the machine learning mo
dels provides an explanation for how much each feature contributes to the model’s p
redictions. We used the shap.KernelExplainer() function, from SHAP Python packag
e (https://shap.readthedocs.io/en/latest/index.html), with our Naïve Bayes to explain
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features’ contributions. The features are ranked in descending order based on the c
omposition ratio or individual feature’s contribution to the model’s explainability. The
first 15 features cumulatively explain 85% of the model’s predictions.

Removing highly correlated features
Highly correlated features are features with high correlation and have almos
t the same effect on the dependent variable. So, by dropping the features with high c
orrelation, we can import storage and computational speed performance. To achieve
this we used pandas.DataFrame.corr(method=’pearson’) function to calculate the pa
irwise Pearson correlation between columns (i.e. features), and lastly we removed th
e features that the PCC > 0.5. This threshold was defined based on the distribution o
f all PCCs (the start of right tail). Features removed using this method are Percent s
equence identity, Shared domains, Mean essentiality of protein-protein interactors, P
ercent of shared protein-protein interactors essential in 90% cell lines (AVANA), Me
an BF score for shared protein-protein interactors, Mean essentiality of coessentialit
y interactors, Percent of shared coessentiality interactors essential in 90% cell lines (
AVANA), Mean BF score for shared coessentiality interactors, Mean essentiality of c
oexpression interactors, Percent of shared coexpression interactors essential in 90%
cell lines (AVANA), Mean BF score for shared coexpression interactors, Total numb
er of coexpression interactors, and Number of shared coexpression interactors.

3.2.8 Models and corresponding parameters
For every model briefly explained below, 30 curated features were used as
input or predictor features, and binarized z-score (based on the empirical rule of 2
standard deviations) as a target variable (1 = SL interaction, and 0 = no interaction).
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Naïve Bayes (NB)
The NB classifier is based on Bayes' theorem and the premise of predictor
independence. The NB model is simple to construct and does not require iterative
parameter estimates, making it ideal for large datasets. The NB is commonly used
because it outperforms more complex classification algorithms while being very
simple and easier to interpret than many other algorithms. In our case, the prior
probability was calculated as a ratio of 1) SL interaction group and 2) a sum of SL
and no interaction groups. The likelihood was an aggregation of all 30 features’
log2odds ratios. The posterior probability, the combination of the prior probability and
the likelihood, with different thresholds was used to evaluate the predictions against
the ‘ground truth’ which was the binarized z-score.

Logistic regression (LR)
LR classifier was run using the sklearn.linear_model.LogisticRegression()
function with the default parameters.

Random Forest (RF)
RF

classification

was

performed

using

sklearn.ensemble.RandomForestClassifier(n_estimators = 600, random_state = 8,
max_features = 0.5, max_depth = 3, min_samples_leaf = 10) function, where
n_estimators is a number of tress in the forest, random_state controls the
randomization of an algorithm, max_features is the quantification of features to
consider when looking for the best split (float value represents the fraction of
features), max_depth is the maximum depth of the tree or a measure of how many
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splits a tree can make before coming to a prediction, and min_samples_leaf is the
minimum number of samples required to be at a leaf node.

Decision tree classifier (DTC)
DTC was done using sklearn.tree.DecisionTreeClassifier(), using the default
samples.

Multilayer perceptron classifier (MLPC)
MLPC

was

performed

using

sklearn.neural_network.MLPClassifier(hidden_layer_sizes=100, activation='identity',
solver='lbfgs',

learning_rate='adaptive'),

where

hidden_layer_sizes

parameter

represents the number of neurons in the hidden layer, activation identifies which
activation function is used for the hidden layer, solver is the solver function for weight
optimization, and lastly learning_rate is the rate for updating weights.

3.2.9. OPTICS (Ordering points to identify the clustering structure) clustering
The list-like matrix of gene pairs and corresponding predicted SL probabilities
was transformed into an all-by-all matrix using the pandas’ df.pivot() function.
OPTICS

clustering

was

applied

on

the

all-by-all

matrix

using

the

sklearn.cluster.OPTICS(max_eps = 0.01, min_samples=100) function, where
max_eps is the maximum distance between two samples for one to be considered as
in the neighborhood of the other, min_samples parameter is the number of samples
in a neighborhood for a point to be considered as a core point. OPTICS does not
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assign cluster memberships to data points, but it rather stores the order in which the
points are processed.

3.2.10. Computational resources
Calculations and modeling were performed using Python 3.8.10, and
complementing libraries, for data manipulation and statistical functions: pandas 1.2.1,
numpy 1.20.1, sklearn 0.24.1, figure generation: seaborn 0.11.1, matplotlib 3.3.4, and
web app development: dash 2.0.0, and plotly 5.2.1. The properties for the used
computational server are:
Architecture:

x86_64

CPU op-mode(s):

32-bit, 64-bit

Byte Order:

Little Endian

Address sizes:

48 bits physical, 48 bits virtual

CPU(s):

32

On-line CPU(s) list:

0-31

Thread(s) per core:

2

Core(s) per socket:

16

Socket(s):

1

NUMA node(s):

1

Vendor ID:

AuthenticAMD

CPU family:

25

Model:

33

Model name:
Stepping:
Frequency boost:
CPU MHz:

AMD Ryzen 9 5950X 16-Core Processor
0
enabled
2200

CPU max MHz:

5083.3979

CPU min MHz:

2200

BogoMIPS:

6800.3

Virtualization:

AMD-V

L1d cache:

512 KiB

L1i cache:

513 KiB

L2 cache:

8 MiB

L3 cache:

64 MiB

NUMA node0 CPU(s):

0 - 31
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3.2.11 Dash-based web interface for probabilistic predictions of synthetic lethality
(POPSICLE)

POPSICLE is built using Dash Enterprise, a python-based framework for creating
interactive web applications. It is composed of four containers: 1) title bar, 2) sidebar where
users can select the gene pair of interest, and a confirmation message which prints the
predicted synthetic lethal probability for a selected gene pair, 3) tab bar and 4) display area.
The five enlisted tabs are genetic interactions (in the display area the distribution of predicted
synthetic lethal probabilities for experimentally tested and all other gene pairs is shown,
Figure 25.), gene 1 interactors (scatter plot showing the ranked other genes interacting with
gene 1, above 0.25 predicted probability), gene 2 interactors, features (shows the table of
features used in the model, with their corresponding categories and sources), and lastly the
about tab.

3.3 Results
3.3.1 Individual features are not predictive of synthetic lethality
Model performance was evaluated considering each feature individually and
combined (all 30 features and sets of selected features) to understand how much
each feature is predictive of synthetic lethality. Cross-validation (see Methods for
details) was used to estimate how accurately the predictive model was performing.
The set of ~217000 gene pairs (Figure 16.), accumulated from the existing CRISPRmediated genetic interaction screens (Table 1.), was subjected to 5-fold resampling,
to define train and test sets. The receiver operating characteristic (ROC) curve,
created by plotting the true positive rate (TPR) against the false positive rate (FPR)
at various threshold settings, was used as a measurement of the model’s
performance. The individual features are just slightly better predictors of synthetic
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lethality than a random prediction (AUC = 0.5) (Figure 20.A).

Coessentiality,

coexpression, and the percent of shared coessentiality interactors essential in 90%
of AVANA cell lines are the three features with the highest AUC values (Figure 20.A).
Functional information and expression data were previously characterized as
potential predictors of the genetic interactions (Madhukar et al., 2015; Pandey et al.,
2010), but it is evident that they alone are not strong enough predictors. In fact, we
observe that increasing the number of features greatly increases the model
performance, especially the first 15 features (Figure 20.B). Afterward, the model
performance increases at a smaller rate. The percent sequence similarity (AUC = 0.5)
was not a great predictor of synthetic lethality, which is opposite to what Kegel et al.
(De Kegel et al., 2021) show in their study. However, Kegel et al. predictions are
based on paralog gene pairs, whereas our dataset consists of both paralog (~1% of
data) and non-paralog pairs (~99% of data), therefore the power of the percent
sequence similarity to predict synthetic lethality between paralog pairs might be
hindered by non-paralog pairs. Furthermore, we split our dataset into paralog and
non-paralog pairs and evaluated the model’s performance (using all 30 features) on
each set individually. We observe a better performance with paralog pairs, meaning
that the predictions of synthetic lethality are more accurate among paralog pairs
(Figure 20.C).
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Figure 20. Combination of features is more predictive of synthetic lethality than
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individual features. A) ROC curves for individual features from the Naïve Bayes
model. The bar plot shows the AUC values for each feature. Most features have AUC
values of 0.5, which is equivalent to a random classifier. B) As the number of features
used in the model increases the model performance increases as well. Shown are
numbers of features on x-axis and corresponding AUC clues for each set of features,
on y-axis. C) ROC curves from a model that uses all 30 features applied separately
on paralog and non-paralog pairs (cross-validation defined test sets). The model
preforms better on a dataset composed only from paralog pairs.

3.3.2 Combination of 15 features provides most of the model’s interpretability
In addition to the AUC-based, two other feature importance and selection
methods were utilized to exploit which features are better at predicting synthetic
lethality, Shapley additive explanation (SHAP) method (S. Lundberg & Lee, 2017),
removing highly similar/correlated and quasi-constant features. SHAP values are
based on Shapley values, a concept coming from game theory, and they quantify the
contribution that each feature brings to the prediction made by the model. Therefore,
SHAP values measured how much of the model’s explainability each feature has as
well as a cumulative interpretation of a model. This approach showed that the
combination of 15 features (Figure 21.A) provides 85% of the model’s interpretation.
The top two features with the largest composition rations are coessentiality and
percent of shared coessentiality interactors that are essential in 90% of AVANA cell
lines, which is consistent with the AUC-values for individual features. Similarly, the
other two feature selection methods, removing highly correlated (Figure 21.B) and
quasi-constant features (see Methods for details), result in subsets of 17 and 16
features (respectively) with greater importance. This confirms that 15 features are
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enough to achieve similar performance to the one the model that uses all 30 features
has (Figure 21.B).

Figure 21. Feature importance and selection methods. A) Features selection based
on Shapley values (SHAP method). Shown are composition (on top x-axis), and
cumulative (on bottom x-axis) ratios. First 15 features are sufficient to explain 85% of
the model. B) Shown are Pearson correlation matrix of all 30 features, and the
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distribution of person correlation coefficients. The red line indicates the cutoff for the
features that are highly similar or correlated.

3.3.3 Comparable model performances on different test sets
In addition to the cross-validation defined test set, the model performances
were evaluated against two additional test sets, previously unseen by the model, from
Parrish et al. study (Parrish et al., 2021). These test sets are composed of 1030
human paralog gene pairs tested with a double-KO approach in PC9 and HeLa cell
lines. Both ROC curves (Figure 22.A) and precision-recall (PR) curves (Figure 22.B)
provide similar measures of model performance for three test sets (cross-validation
AUC = 0.66, Parrish et al. PC9 AUC = 0.68, and Parrish et al. Hela AUC = 0.71).
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Figure 22. Consistent model performances across different test sets. A) ROC curves
from the model with all 30 features for cross-validation defined test set (black),
datasets from Parrish et al. study, screened in PC9 cell line (blue), and HeLa cell line
(red). The AUC values for all three sets are similar ( 0.05 std). B) Color coding same
as in (A). Shown are precision-recall curves. C) Bar plot shows the similar AUC
values for three test sets from a model with 30 features, without quasi-constant
features, without highly correlated features, and with 15 features selected with SHAP
method. Color coding as in (A) and (B).

3.3.4 Different models perform similarly on the three test sets
To ensure that our results weren’t the outcome of overfitting the original, Naïve
Bayes model, we have employed several other models (Random Forest (RF), Logistic
regression (LR), Decision tree classifier (DTC), and Multilayer perceptron classifier
(MLPC), see Methods for details) to predict synthetic lethality. All models but DTC
exhibit the same performance (AUC = 0.66) when both paralog and non-paralog pairs
are included in the train and test sets (5-fold cross-validation) (Figure 23.A), while RF
model overperforms other models when paralog pairs and non-paralog pairs are used
separately (Figure 23.B-C).
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Figure 23. ROC curves for different models. The ROC curves for five models (naïve
bayes NB - black, random forest FR – red, logistic regression LF – blue, decision tree
classifier DTC – orange, and multilayer perceptron classifier MLPC – purple), for
cross-validation test sets including both paralog and non-paralog pairs (A), and
paralog (B) and non-paralogs pairs (C) individually.

3.3.5 Scaling the predictions genome-wide
After assessing all variables (feature importance and selection, computing
resources, etc.) we selected the Naïve Bayes model with 15 features that explain
85% of the model to scale the predictions to all possible gene pairs in the human
genome (~182 million pairs) (Figure 24.). The ~220000 gene pairs acquired from the
existing studies are only 0.12% of all possible gene pairs in the human genome. This
minute percent of the experimentally tested gene pairs shows the large gap of
untested gene pairs and equally large search space for investing genetic interactions.
Predictions made in this study provide an initial filter for selecting the pairs that exhibit
some potential for being SL interaction, particularly pairs with probability values
above 0.25. To aid with further exploration of these predictions, we created the userfriendly interface, POPSICLE (see methods for details) where users can select a gene
pair of their interest and obtain its probability for being a synthetic lethal pair, as well
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as browse through the other interactors with the two genes from a user-defined pair
(Figure 25.).

Figure 24. Predicted probabilities for all possible gene pairs in the human genome.
Two violin plots are representative of pairs that were included in the training set (no
interactions and negative interactions groups (Figure 16.) (red), and all other possible
pairs (blue). The number on the right indicates number of pairs for each bracket,
defined by two dashed lines.
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Figure 25. POPSICLE overview – the display is showing the distribution of predicted
synthetic lethal probabilities (>0.25). The dashed line marks the position of user-queried gene
pair.

3.3.6 Conserved SL interactions
We compared the set of conserved SL interactions, defined by Srivas et al.
(Srivas et al., 2016), and negative genetic interactions from the global map of genetic
interactions in yeast, constructed by Costanzo et al (Costanzo et al., 2010b, 2019).
Srivas et al. defined two conserved cancer networks (CoCaNets) of SL interactions
at two cutoffs 10% (172 interactions) and 2% (36 interactions) which are likely to be
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observed in both human and yeast models. We overlapped the 172 interactions with
our predictions and observed that 44 (25%) of those interactions have predicted
probabilities higher than 0.2 of being SL interactions (Figure 25.A-B). The probability
= 0.2 was used as a threshold because that is where the long tail of the distribution
starts, indicating the occurrences that are far from the central part of the distribution
and characterizing more likely SL candidates. The set of negative genetic interactions
was filtered from the yeast global map of genetic interactions (https://thecellmap.org)
was using the genetic interaction score < 0.12 as a cutoff defined by Costanzo et al.
(Costanzo et al., 2016). Next, from this set which consisted of ~40000 negative
interactions, we kept only those pairs that have human orthologs. The final set
resulted in ~14000 interactions, and for 759 of those interactions, our probability
predictions

are

above

0.2

(Figure

25.A-B).

Figure 26. Conserved interactions. A) Distributions of predicted probabilities for a set
of conserved SL interactions (in yeast and human) from Srivas et al. and set of
negative interactions from the global map of genetic interactions in yeast from
Costanzo et al. Violin plots are color coded as in Figure 24. Dashed line indicates the
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threshold that used to find the interception of these two sets and our predictions made
in this work. B) Intersection plot for the two sets and our predictions.
3.4. Discussions
Synthetic lethality provides a treatment approach for cancers driven by the loss
of function of tumor suppressor genes, and amplification and/or overexpression of
genes that cannot be targeted directly. However, despite this great premise, very few
SL interactions have been translated into clinical uses. The most well-known example
is the synthetic lethality between BRCA1/2 and PARP genes, targeted with PARP
inhibitor olaparib in cancers with BRCA1/2 loss of function (Lord & Ashworth, 2008,
2017). Few other examples from pre-clinical and clinical studies are mentioned in the
review by Li et al. (S. Li et al., 2020). Some of the mechanisms and cellular processes
these interactions are aimed to address the regulation of cell proliferation,
differentiation, senescence, and apoptosis, the repair of DNA single- and doublestrand breaks, or complexes involved in these processes, such as targeting of
SWI/SNF complex, which is involved in controlling the cell cycle, DNA replication, and
repairing DNA damage. Most of the SL interactions discovered thus far are contextspecific, making it very challenging to devise a generic and context-independent
approach for identifying SL interactions. The work described in this chapter is aimed
to address this challenge by predicting the probability of being SL for any given pair,
therefore proving a baseline SL probability for all possible gene pairs in the human
genome, independent of the molecular or cancer context.
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3.4.1. Narrowing the search space for investigating SL interactions in human
cells
The performance of our model, therefore the accuracy of our predictions, when
tested with multiple datasets was acceptable (AUC = 0.68  0.05) but not excellent.
However, it is still very relevant as it allows us to predict the SL probability for all
possible pairs, which is the first genome-wide view of potential SL interaction.
Additionally, these predictions exude the potential for optimizing the search space for
investigating the genetic interactions, therefore reducing the efforts and time to
perform these experiments. The clusters enriched for potential SL interactions can
be investigated by applying clustering algorithms on an all-by-all matrix (size =
~18000 x 18000), where rows and columns are genes, and values are predicted
probability obtained by transforming the current list-like matrix (size = ~182x106, rows
=gene pairs, column = predicted probability) of our predictions. However, it must be
noted that the clustering, as well as the other steps in this approach such as
generating and calculating features, and model training are computationally
expensive. For example, the OPTICS (see Methods for details) clustering algorithm
takes ~12h to compute core distance and reachability distance for every data point
subjected to clustering which are parameters necessary to assign cluster
memberships.

3.4.2. Towards validating the predictions
Scalability is the main issue when it comes to exploiting and testing genetic
interactions in human cells. However, the genome-wide predictions from this work
and advancements in CRISPR multiplex technology make this issue addressable to
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some level. The future directions of this study are geared towards experimental
validation of these in silico predictions. The enCas12 multiplex platform is currently
the ultimate approach for combinatorial editing. The Cas12a endonucleases are a
promising tool for multiplexed genetic perturbations because they can process
multiple gRNAs expressed as single transcripts and cleave target DNA (McCarty et
al., 2020), while subsequently decreasing the library size and reducing the time and
cost of experiments. For a wider adoption of Cas12a in screening systems, DeWeirdt
et al. optimized enAsCas12a for pooled, combinatorial screens in the human cells
(DeWeirdt et al., 2021).
In the enCas12a multiplex screening, the cells of interest are first transduced
with the expression vector encoding the EF1a promoter, which drives the enCas12a
enzyme expression (Addgene: #136476). Afterward, transduced cells are subjected
to antibiotic selection to eliminate the non-transduced cells. In this instance, it is
blasticidin selection because the selectable marker encoded on this expression
vector is blasticidin. Next, the cells expressing the enCas12a enzyme are transduced
with the lentiviral dual-guide expression vector (Addgene: # 136474). The selectable
marker in this vector is puromycin, therefore non-transduced cells are eliminated by
puromycin treatment. Lastly, the replicates are seeded, and cells are passaged for a
certain number of doublings before the screen termination. This approach has
already been tested by our lab (Dede et al., 2020; Lenoir et al., 2021) and externally
(DeWeirdt et al., 2021) showing promising results. Moreover, there are ongoing efforts
within our lab and others in the field for engineering 4 and higher-order lentiviral expression
constructs, which would allow simultaneous perturbation of 4 or more genes, massively
reducing the size of such experiments.
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3.4.3. Which gene pairs to validate?
The number of “more likely” candidate SL interactions (probability > 0.2, n =
~1200000) is a small subset (0.66 %) of all possible pairs. However, an even smaller set
would be more favored for the first pass of experimental validation. When it comes to
selecting such a set of predicted interactions for the experimental validation, there are a few
approaches we can take. We could either focus only on interactions within 1) a defined class
of genes, e.g., all kinases, all regulatory genes/transcription factors (TFs), all transporters,
etc., 2) a specific pathway e.g., DNA repair, metabolism, etc., or 3) a set composed of a
number of interactions derived from each probability bracket (Figure 24.). Each of these
choices has its benefits and constraints, for example, the benefit of focusing on interactions
between kinases is the vast amount of knowledge about the druggable kinome (Cichońska
et al., 2021; Paul et al., 2020; Ravikumar et al., 2019) (https://kinase-atlas.bu.edu/index),
meaning that translating a kinases’ fostered SL interactions to clinical studies and uses would
be faster as there already exists a significant number of kinase drugs. On the other hand, the
constraint of targeting kinases in cancer backgrounds is triggering of cells to acquire
resistance to chemotherapy (Bhullar et al., 2018), essentiality neutralizing the kinase-based
treatment. Additionally, a good filter for selecting which gene family to target is looking at the
essentiality and expression of genes in that family across the array of cell lines (Depmap and
CCLE collection of cell lines). Ideally, a good gene family to investigate would be the one in
which most genes exhibit moderate or modest phenotypic effects and are expressed. The
advantage of experimentally validating the set composed of a number of interactions picked
from each probability bracket (Figure 24.) is that it would directly assess the precision of
predictions and accuracy of our computational modeling. Additionally, it holds a promise of
allowing the identification of gold standard SL interactions. The last two brackets of SL
probability distribution are enriched for pairs (n = 2385) that have already been experimentally
tested in human cells. However, only ~28% (n = 684) of these tested and predicted as SL
interactions are scored as SL interactions in the original CRISPR-based genetic interaction
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studies. Therefore, if this secondary experimental validation confirms these 684 interactions
as SL interactions, then this set can serve as a potential pool of gold standard SL interactions.

Hypothetical enCas12a library for experimental validation
Say a set of ~3500 (2385 from the top two probability brackets, 900 from the other
three brackets, 300 from each, and the rest ~215 are control pairs) gene pairs is selected for
the experimental validation. To describe the scenario that would require the most liberal
library design, all genes in the pairs are unique, so there are ~7000 unique genes. Each of
these genes is targeted with four enCas12a gRNAs acquired from DeWeirdt et al. library
(DeWeirdt et al., 2021), and every pair is targeted with all 16 combinations of guides (a
previous study by Dede et al., showed that there is no position effect, therefore only single
A-B orientation is teste). This gives us a library with ~85000 contracts, comparable to the
single KO genome-wide library (e.g., TKOv3).

Another concept that has an important role in this discussion is the molecular context
or a cell line in which this experimental validation should be performed. As there does not
exist a thing such as ‘reference’ human cell line this poses a big challenge when it comes to
establishing a consensus about genetic interactions, in particular SL interactions in human
cells. This is another reason why creating and mapping a global map of genetic interactions
in the human cells is still way far behind the yeast’s global map of genetic interactions which
was mapped out a decade ago. Two options that one can proceed with here are to select 1)
a (CRISPR friendly) cell line with a simple and normal karyotype (e.g., RPE1 cell line) and
large-scale exploit genetic interactions in fine resolution, or 2) a panel of cell lines with
different molecular built-ups to exploit smaller-scale (interactions within a certain pathway, or
a gene group). These approaches would reveal different information, the first one provides
‘deep’ knowledge with the ability to reveal the genetic interaction hubs in a particular

95

background, whereas the second one supplies ‘wide’ understanding and characterization of
a small set of genetic interactions. However, both routes are necessary to unify our
understanding of human functional genomics, therefore allowing us to leverage that
knowledge for devising treatment strategies and improving clinical outcomes.
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Chapter 4: Contributions to collaborative studies

Earlier in this dissertation, I have mentioned that the drugZ (Colic et al., 2019)
is a multifaceted method. In this chapter, I will highlight some of the collaborative
studies in which the drugZ was instrumental for analyzing and identifying hits and
candidate therapeutic targets, and my contributions to these studies.

4.1. Neuronal and mouse HD essential gene

The analysis described in this section is adapted from the published study:
Wertz, M. H., Mitchem, M. R., Pineda, S. S., Hachigian, L. J., Lee, H., Lau, V.,
Powers, A., Kulicke, R., Madan, G. K., Colic, M., Therrien, M., Vernon, A., BejaGlasser, V. F., Hegde, M., Gao, F., Kellis, M., Hart, T., Doench, J. G., & Heiman, M.
(2020). Genome-wide In Vivo CNS Screening Identifies Genes that Modify CNS
Neuronal

Survival

and

mHTT

Toxicity.

Neuron,

106(1),

76-89.e8.

https://doi.org/10.1016/j.neuron.2020.01.004. The article is published under the
Elsevier license which states:
“Please note that, as the author of this Elsevier article, you retain the right to
include it in a thesis or dissertation, provided it is not published commercially.
Permission is not required, but please ensure that you reference the journal as the
original source. For more information on this and on your other retained rights, please
visit: https://www.elsevier.com/about/our-business/policies/copyright#Author-rights”.

This study by Wertz et al. reports the results of the first genome-wide genetic
screens in the central nervous system (CNS) using both shRNA and CRISPR
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libraries. Analysis of these screens led to the identification of several gene classes
essential for CNS neurons and showed that CNS neurons in addition to being
sensitive to perturbations to synaptic processes are also sensitive to autophagy,
proteostasis, mRNA processing, and mitochondrial function. As these processes and
pathways are known to be implicated in multiple neurodegenerative diseases, the
same screening approaches were applied to two mouse models of Huntington’s
disease (HD) to identify disease-specific genetic vulnerabilities.

Screen Analysis
As the genome-wide library contains on average 4-6 shRNAs targeting each
gene, and the Asiago library contains 4 sgRNAs per gene, examining the combined
effect of more than one genetic perturbation per gene assists in assessing the
possibility off-target or seed-based effects. Relative library representation was
determined as described in the manuscript, and the drugZ algorithm was used to rank
each gene’s relative depletion in the screen based upon the relative recovery of the
shRNAs or sgRNAs. Briefly, DrugZ determines the fold change of each shRNA or
sgRNA reagent relative to a user-specified control sample, in this case the initial
plasmid pool. The variance for each fold change is estimated based on the distribution
of fold changes for the 1,000 reagents with most similar abundance in the control
sample. Using this variance estimate, a Z-score is calculated for each reagent, and a
gene-level Z-score is determined by summing the reagent-level Z-scores and
normalizing by the square root of the number of reagents, yielding the final normZ
score. P values are calculated based on the standard normal distribution and false
discovery rates are estimated using the method of Benjamini & Hochberg. We used
a log2 gene expression > −1 in WT striatum cutoff to identify genes expressed in the
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striatum. In the WT shRNA screen, sum normZ scores showed a bimodal distribution
(Figure 26.A-C). We fit the data with a two-component Gaussian mixture model (using
the mixtools package in R) approximating hits (essential genes) and non-hits (genes
with no knockdown phenotype) (Figure 26.D). False discovery rate at a given normZ
score was calculated as the ratio of the areas under the Gaussian models for all
values less than normZ. At the intersection of the Gaussian models at normZ score
0.005, FDR was estimated as 0.038; this cutoff was used as the empirical threshold
to determine neuronal essential candidate genes (Figure 26.E). In all other screens
a threshold of normZ p value < 0.05 was used to determine candidate ‘hits’. Data
analysis revealed a number of targets that replicated between screen modalities
(shRNA and sgRNA) and mutant models (R6/2 and zQ175).
Figure 27. Identification of Neuronal Essential Genes by Pooled Genome-wide In
Vivo Screening. A) and B) Contour plots of normZ scores versus log2 WT striatal
gene expression for the 7-month (A) and 4-week (B) shRNA screens. C) Scatterplot
of the log2-normalized fold change in WT compared to input library at 4 weeks versus
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7 months after in vivo incubation with the genome-wide shRNA library. Green points
represent individual shRNA hairpins with an average of >1 log2 fold depletion in
shRNA representation at 4 weeks and 7 months. Pearson correlation r = 0.78. D)
Density plot of the sum normZ scores for the WT shRNA screens shows a bimodal
distribution overlaid with two Gaussians to highlight the depleted essential genes
(green) as compared to the non-essential genes (black). Genes were identified as
candidate neuronal essential genes below the threshold of the intersection of the two
Gaussians (red dotted line). E) Plot of normZ values versus rank of candidate
neuronal essential genes. Top candidate essential genes in relevant biological
pathways are highlighted in color as marked. The figure is used with permission from
Mary Wertz, Ph.D. (panels A, B, and D created by me, and panels D, and E by Dr.
Wertz). Copyright permission granted by Elsevier license.

4.2. CRISPR-Cas9 DNA damage response (DDR) screens

The work described in this section comes from a study published by Su, D.,
Feng, X., Colic, M., Wang, Y., Zhang, C., Wang, C., Tang, M., Hart, T., & Chen, J.
(2020). CRISPR/CAS9-based DNA damage response screens reveal gene-drug
interactions. DNA Repair, 87, 102803. https://doi.org/10.1016/j.dnarep.2020.102803.
The article is published under the Elsevier license as well, and copyright permission
is granted.

DNA damage response (DDR) is a process that is crucial for cell survival,
genome maintenance, and whose deficiencies have been exploited therapeutically in
cancer treatment. This study provides a comprehensive map of DDR chemogenetic
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interactions. The map is a result of screens performed using a custom CRISPR library
targeting 365 DDR genes (derived from TKOv3 whole-genome library) and several
DDR inhibitors and DNA-damaging agents in 293A cells. This map revealed known
genetic modifies of these agents, and novel synergistic interactions between
POLE3/4 and an ATR inhibitor, a PARP inhibitor, and camptothecin, a topoisomerase
inhibitor. Lastly, this study also demonstrates that the TP53 status does not affect the
outcome of the screens.

Data analysis for this study is portioned in three steps: 1) processing, and
aligning raw data followed by extracting read count for each construct or sgRNA, 2)
comparing treated and untreated samples to evaluate the potential chemogenetic
interactions, and 3) additional comparisons - CRISPR DDR screen and wholegenome screen in the same cell line, and comparison of CRISPR DDR screens
according to TP53 status. I have performed the initial analysis using our (Hart lab) inhouse pipeline for processing and extracting read counts from CRISPR screens
outlined as following: 1) unzip all fastq.qz (file format for the raw data), 2) merge all
lanes into one sample, 3) check the quality of reads in fastq files, 4) if necessary, trim,
clip and reverse the reads, 5) map the reads using Bowtie aligner, and finally 6) collect
and count reads. After obtaining the read counts in a matrix format, where rows are
sgRNAs used in the library, and columns are samples (treated and untreated in
replicates), I used drugZ to compare the sgRNA abundances between treated and
untreated samples and identify genetic modifier of used agents’ activity. DrugZ is
primarily developed for the analysis of whole-genome screens, therefore tunning of
half_window_size parameter was necessary when it was run on data from these
screens done with DDR library, which is a smaller custom library. The untreated or
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control samples from these screens, and whole-genome TKOv3 library-based screen
in the same cell line 293T, were also subjected to BAGEL analysis to calculate
essentiality scores. The BF or essentiality scores of DDR genes from the two
separate screens were compared, and this analysis showed the consistency of the
whole-genome and sub-library screens for assessing gene functions. Lastly, to
evaluate the CRISPR screens according to TP53 status, we investigated the data
from DepMap (AVANA 2018Q4), composed of >500 CRISPR KO screens. We used
the F-measure, which is the harmonic mean of the precision-recall calculated for each
screen at BF = 5, to evaluate the performance of these CRISPR screens. From this
comparison, we observed a similar screen performance in TP53 wild-type (WT) and
TP53-mutated cancer cell lines. This computational observation was solidified with
experimental validation, which also showed that the status of TP53 does not influence
the screen performance.

4.3. The use of drugZ to compare isogenic CRISPR screens
Isogenic pairs of cell lines, which differ by a single genetic modification, are
powerful tools for understanding gene function. Performing isogenic knockouts, or
performing CRISPR screens in such isogenic cell lines, can be used for identifying
genetic interactions between the gene used to generate the isogenic status and other
genes targeted with the CRISPR library used in a screen. If both original and derived
isogenic lines are targeted with the same CRISPR library, then drugZ can be used to
compare these backgrounds and identify potential genetic interactions between the
gene used to create the isogenic line and all other genes targeted by a library. This
approach for identifying and quantifying genetic interactions from isogenic CRISPR
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screens with drugZ is established internally through the collaboration with a few labs
within the institution (MDA – Gan lab, DePinho lab, and Chen lab) who are conducting
isogenic screens in different molecular and cancer backgrounds.
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Chapter 5: Discussion and final remarks

The first traces of systems-oriented studies in specific subfields of biology were
observed in the middle of the 20th century. However, it was not until the mid-1990s
and completion of the first whole-genome sequencing (Fleischmann et al., 1995) that
systems biology had gained traction. Systems biology is commonly defined as the
efforts to investigate the behavior and interactions of all of the components in a certain
biological system while it is functioning (Ideker et al., 2001). Its fraternal twin,
functional genomics focuses on understanding the functional role of these
components (e.g., genes, proteins) and explaining how they contribute to different
processes happening in the system.
The arrival of CRISPR technology and its ability to facilitate large-scale
functional studies in human cells shed light on deciphering the hierarchical assembly
of human cells. In this dissertation, I have described my computational efforts to
analyze and model CRISPR-generated functional data, in the forms of chemogenetic
and genetic interactions, both of which have the potential to decode the diseasespecific molecular underpinnings and lead to the novel treatment strategies. This
work has addressed some of the unmet needs but had also generated new questions
relevant to the field.
Before the CRISPR technology, yeast was the model of choice for genetic
studies, because it is a simple single-celled organism, and it shares many basic
properties with human cells. However, CRISPR technology and its multifaceted
editing nature have put the spotlight on human cells. The most used CRISPR
applications are briefly discussed in Chapter 1, and two of them, chemogenetic and
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combinatorial genetic editing, instrumental for the work presented in this dissertation,
are discussed in detail.
To address the gap in identifying and quantifying chemogenetic interactions in
CRISPR screens we developed the drugZ algorithm. CRISPR-mediated drug
screens, which facilitate the simultaneous chemical and genetic editing, were
performed mostly in positive selection screens because performing them in negative
selection screens, often used to identify the depleted genes, was more challenging
and there was no adequate analytical method to evaluate and robustly score
chemogenetic interactions in such screens. The implementation, benchmarking of the
algorithm, its variant drugGS, statistically more rigorous and computationally more
demanding approach, and the evaluation of experimental parameters is covered in
chapter 2.
Comprehensive analysis of new CRISPR-based drug screens and reanalysis
of existing screens with drugZ revealed a set of tumor suppressor genes as frequent
drug suppressor hits. We hypothesized that these hits are drug-independent
proliferation suppressors. A study by Lenoir et al. (Lenoir et al., 2021) from our labtested this hypothesis and provided a model-based approach for systemic
identification of these proliferation suppressors.
Despite the successful finding from these screens, there are some limitations
to chemogenetic screens. One such limitation is screening cell lines in which certain
genes are inactivated, therefore limiting the identification of potential interactions
between the inactivated gene and a drug or chemical agent used in the screen.
Another limitation of these screens is the lack of confidence in the interactions
between essential genes and chemical agents because guides targeting the essential
genes are depleted rapidly for cell populations and weaken the statistical power for
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these interactions. Lastly, in the past two years, drugZ has proven to be robust and a
method of choice when it comes to the analysis of chemogenetic screens and
identification of genetic modifiers of drug activity.

PARP1 inhibitors and deficiency of BRCA1/2 genes is the most eminent proof
that synthetic lethality has the potential to outmaneuver a cancer genome. However,
obstacles such as tumor heterogeneity and complexity, the lack of understanding of
synthetic lethal interactions, drug resistance, and screening challenges are masking
this potential and limiting the clinical translation. Chapter 3 summarizes the history of
genetic interactions, specifically synthetic lethal interactions. Next, it identified the gap
in the field based on observation from existing CRISPR-mediated genetic interaction
screens, and that is very few synthetic lethal interactions are reproduced as
significant in multiple studies, and most of these interactions are highly contextspecific.

To address this gap, we proposed a Bayes theorem-driven approach to

predict context-independent synthetic lethality from existing CRISPR genetic screens
combined with essentiality, expression, protein / genomic neighborhood, and DNA
sequence – relevant data encoded as 30 different features.
Examining the features’ importance and relevance for the model’s
performance through three different methods revealed that a combination of ~15
features has nearly the same predictive power as all 30 features. In terms of which
features predict better than the others, essentiality and protein neighborhood-related
features outperform the others. The models’ (with all 30 and reduced sets of features)
performances were tested against three different test sets and similar results across
all combinations are observed (AUC = 0.68  0.05). We have also examined the
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model’s performance on paralog and non-paralog pairs separately, in addition to the
dataset containing both paralog and non-paralog pairs. The model performs better
when applied only on paralog pairs (AUC = 0.69), confirming that paralogs indeed
are a rich source for identifying synthetic lethal interactions (Dede et al., 2020). For
additional computational validation of the model, two recent studies (Ito et al., 2021;
Thompson et al., 2021) exploiting synthetic lethality in human cells with CRISPR dual
editing, can be utilized as validation sets as well. There were not included in the
training/testing of our model because they haven’t been publicly available at that time.
It is worth mentioning, that both studies target and exploit paralog gene pairs. And
we already know that our model performs better on paralog pairs than non-paralog
or a combination of both paralog and non-paralog gene pairs.
Additionally, to ensure that these conclusions are model agnostic, we
examined four other supervised learning models (RF, LR, DTC, and MLPC), and
observed that our original NB model and RF model are highly similar and outperform
the other models. After all comparisons, the model selected for scaling up and
predicting the synthetic lethal probability for all other gene pairs was the NB model
with 15 features (based on SHAP method scoring). This is the first genome-wide
assessment and molecular context-independent synthetic lethality quantification
attempt. The predictions made by our model are not the optimal ones, however, they
can be used to optimize the search space for investigating synthetic lethality.
Moving towards the experimental validations of these predictions depends on
a set of questions, each equally important and challenging to address. Which subset
of pairs to validate do we focus on certain gene family, or a pathway, or select the
pairs based on where on the distribution of predicted probabilities do they lie at? What
cell line do we test them in? – or do we test an even smaller set in a panel of different
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cell lines? Which screening platform to use, how to design the targeting CRISPR
library? However, addressing these questions calls for another PhD marathon outside
of this dissertation. Nevertheless, in chapter 3 I do offer some insights about how
these questions can be addressed in the future directions.
Another limitation of our efforts here is that we are only exploiting the
digenic genetic interactions, therefore omitting the whole well of higher-order genetic
interactions. If we set our expectations based on the knowledge from yeast studies
about complex genetic interactions, which estimate that just the next order
complexity, the trigenic interactions network is ~100-fold larger than the global digenic
network (Kuzmin et al., 2018), we can understand the magnitude of information that
we are missing out. The beam of light that can enlighten this entanglement of complex
genetic interaction I see in the ongoing efforts towards engineering and designing the
greater than dual multiplex CRISPR libraries. Noteworthy is also the fact that all these
advancements in technology immediately call for complementing computational
methods to analyze and quantify the generated data. And not to mention the fact that
even when it comes to analyzing and scoring digenic genetic interaction in human
cells there is still no consensus for an ultimate scoring method. However, none of
these limitations, neither experimental nor analytical, will prevent CRISPR editing
from continuing to be a fast-moving field revolutionizing cancer research.

Finally, the work presented in this dissertation can be continued in any of the
following three directions, 1) basic biology – to continue expanding our knowledge
about both chemogenetic and genetic interactions in human cells for the purpose of
understanding the extraordinary assembly of human cells and all their processes, 2)
technology advancements based on optimized, less time and efforts consuming
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experimental designs, and lastly, 3) translational research, as these efforts
collectively create an avenue for devising novel treatment strategies, and improving
patient stratification and drug efficacy.
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